Asthma — RepurpOS | OpenSourceMedicine

Disease overview

Alterations

113

Molecular (A)

100

Clinical (B–E)

Direct drugs

437

Via biomarker

207

Natural agents

Natural products

128

Merged ranked

642

With trial/literature evidence

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed MeSH, PubMed Literature, PubMed NP · Pipeline phase 7 · Updated 2026-07-05

Remission & chronicity

Spontaneous remission

26% of childhood-onset asthma in clinical remission by adulthood; <20% adult-onset achieves sustained remission; 65% long-term remission in mild-moderate vs 16% in severe

Best-intervention remission

Biologics (anti-IL-5, anti-IL-4/13, anti-IgE) achieve near-zero exacerbation rates in eligible severe patients; allergen immunotherapy (AIT) achieves sustained drug-free remission in allergic asthma in ~30-40% of treated patients

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Moderate; highly severity-dependent; large practice gap for AIT

Primary barrier

biological (severe phenotype) + practice (AIT underutilized)

Barrier detail: Allergen immunotherapy is the only disease-modifying treatment for allergic asthma and is underused relative to guidelines; biological phenotyping (T2-high vs T2-low) drives outcomes more than treatment intensity alone

Last SoC change: 2022 — GINA guidelines introduced 'anti-inflammatory reliever' strategy (ICS-formoterol as reliever replacing SABA monotherapy); biologics formally endorsed as step 5 since ~2016; ICS as first-line unchanged since 1990s

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0004979 · MESH: D001249 · UMLS_CUI: C0004096

Right to Try Relevance

Eligibility: This disease meets the federal and state right-to-try legal standard (21 U.S.C. § 360bbb-0a and Montana SB 535): it lacks disease-modifying therapy with indication-specific FDA approval. Patients with Asthma may be eligible to access investigational therapies outside of clinical trials under right-to-try frameworks.

Investigational Agents

343

Phase 3: 75, Phase 2: 218, Phase 1: 50

Most Advanced Phase

Phase 3

Highest dev. stage

Gene Targets

113

Actionable

Pipeline Compounds (Top 6)

Darapladib, Fenretinide, Aspirin, Azithromycin, Cholecalciferol, Clarithromycin

Legal Standard: Right-to-try requires the disease lacks "adequate approved therapy for that specific disease" (not symptom-management drugs). This distinction means a disease with antidepressants available still qualifies if no FDA approval exists for THAT disease indication.

View Right-to-Try Compendium

Alterations

113 total · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
Anxiety	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Asthma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Childhood onset	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hyperventilation	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
ADAMTSL3 ADAMTS like 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADORA1 adenosine A1 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADORA2A adenosine A2a receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADORA2B adenosine A2b receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADORA3 adenosine A3 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRA1A adrenoceptor alpha 1A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRA1B adrenoceptor alpha 1B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRA1D adrenoceptor alpha 1D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRA2A adrenoceptor alpha 2A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRA2B adrenoceptor alpha 2B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRA2C adrenoceptor alpha 2C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRB1 adrenoceptor beta 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRB2 adrenoceptor beta 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRB3 adrenoceptor beta 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AHI1 Abelson helper integration site 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ALOX5 arachidonate 5-lipoxygenase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
APOE apolipoprotein E	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Asthma Control Test (ACT)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
At 3 months of treatment: Change from baseline of the FEV1 and PEFR (also %predicted); Number of patients without asthma symptoms	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
BACH2 BACH transcriptional regulator 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BCL2L11 BCL2 like 11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BLTP1 bridge-like lipid transfer protein family member 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CARD11 caspase recruitment domain family member 11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD247 CD247 molecule	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDHR3 cadherin related family member 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CHRM1 cholinergic receptor muscarinic 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CHRM2 cholinergic receptor muscarinic 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CHRM3 cholinergic receptor muscarinic 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CHRM4 cholinergic receptor muscarinic 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CHRM5 cholinergic receptor muscarinic 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CSF2 colony stimulating factor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CYSLTR1 cysteinyl leukotriene receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Changes From Baseline in Morning Peak Expiratory Flow (PEF) and Trough Evening PEF Averaged Over the Entire Post-baseline Period	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Changes in lung function (FEV1)	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
D2HGDH D-2-hydroxyglutarate dehydrogenase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Differences in asthma control inter-group	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
FLG filaggrin	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FTO FTO alpha-ketoglutarate dependent dioxygenase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GATA3 GATA binding protein 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GLB1 galactosidase beta 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GNA15 G protein subunit alpha 15	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GSDMB gasdermin B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HDAC7 histone deacetylase 7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ID4 inhibitor of DNA binding 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IGHE immunoglobulin heavy constant epsilon	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL13 interleukin 13	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL18R1 interleukin 18 receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL18RAP interleukin 18 receptor accessory protein	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL1RL1 interleukin 1 receptor like 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL2 interleukin 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL21R interleukin 21 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL2RA interleukin 2 receptor subunit alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL33 interleukin 33	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL4R interleukin 4 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL5 interleukin 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL5RA interleukin 5 receptor subunit alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL6 interleukin 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL6R interleukin 6 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL7R interleukin 7 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IPCEF1 interaction protein for cytohesin exchange factors 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IRAG1 inositol 1,4,5-triphosphate receptor associated 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IRF1 interferon regulatory factor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ITGB8 integrin subunit beta 8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
JAK2 Janus kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
JAZF1 JAZF zinc finger 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
LPP LIM domain containing preferred translocation partner in lipoma	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
LRRC32 leucine rich repeat containing 32	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MYC MYC proto-oncogene, bHLH transcription factor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NFKBIA NFKB inhibitor alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NOD2 nucleotide binding oligomerization domain containing 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NPNT nephronectin	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NR3C1 nuclear receptor subfamily 3 group C member 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
OTULINL OTU deubiquitinase with linear linkage specificity like	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDCD1 programmed cell death 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE3A phosphodiesterase 3A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE3B phosphodiesterase 3B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE4A phosphodiesterase 4A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE4B phosphodiesterase 4B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE4C phosphodiesterase 4C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE4D phosphodiesterase 4D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PLXNC1 plexin C1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PRKCQ protein kinase C theta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PTPRC protein tyrosine phosphatase receptor type C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RUNX1 RUNX family transcription factor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RUNX3 RUNX family transcription factor 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Rate and Extent of Absorption of Three Dose Levels of AZD7594 Following Multiple Dose Administration by Assessment of AUC(0-24) of AZD7594	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
SERPINB7 serpin family B member 7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SERPING1 serpin family G member 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SHARPIN SHANK associated RH domain interactor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SLC22A5 solute carrier family 22 member 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SLC39A8 solute carrier family 39 member 8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SMAD3 SMAD family member 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SUOX sulfite oxidase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TBL1XR1 TBL1X/Y related 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TESPA1 thymocyte expressed, positive selection associated 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TLR1 toll like receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TNFRSF8 TNF receptor superfamily member 8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TNFSF4 TNF superfamily member 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TPD52L3 TPD52 like 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TRAF3 TNF receptor associated factor 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TSLP thymic stromal lymphopoietin	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TSPAN8 tetraspanin 8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
USP8 ubiquitin specific peptidase 8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
WDR36 WD repeat domain 36	Molecular	Gene	—	—	Emerging	Open Targets	Ensembl Open Targets
ZNF217 zinc finger protein 217	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ZNF652 zinc finger protein 652	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
number of exacerbations	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
number of hospitalization	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
saturation	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—

FDA-Approved Therapies

Phase 4 agents with regulatory approval for this indication

Drug Name	Mechanism	Type
ACETAZOLAMIDE	None	Gene-targeted
ADENOSINE	agonist; agonist	Gene-targeted
ALBUTEROL SULFATE	None	Direct
ALFUZOSIN	inhibitor	Gene-targeted
ALFUZOSIN HYDROCHLORIDE	agonist	Gene-targeted
AMINOPHYLLINE	inhibitor	Gene-targeted
AMINOPHYLLINE	None	Direct
AMIODARONE HYDROCHLORIDE		Gene-targeted
AMITRIPTYLINE HYDROCHLORIDE	inhibitor	Gene-targeted
AMPHETAMINE	None	Gene-targeted
APOMORPHINE	inhibitor	Gene-targeted
APRACLONIDINE	agonist	Gene-targeted
APRACLONIDINE HYDROCHLORIDE	agonist	Gene-targeted
ASENAPINE		Gene-targeted
ASPIRIN		Gene-targeted
ATENOLOL		Gene-targeted
ATIPAMEZOLE	inhibitor	Gene-targeted
ATROPINE	inhibitor	Gene-targeted
BECLOMETHASONE DIPROPIONATE	None	Direct
BENZPHETAMINE		Gene-targeted
BETAMETHASONE ACETATE	None	Direct
BETHANIDINE		Gene-targeted
BICALUTAMIDE	None	Gene-targeted
BRIMONIDINE	agonist	Gene-targeted
BRIMONIDINE TARTRATE	agonist	Gene-targeted
BROMOCRIPTINE	inhibitor	Gene-targeted
BUDESONIDE	None	Direct
CABERGOLINE	inhibitor	Gene-targeted
CAFFEINE	inhibitor; inhibitor	Gene-targeted
CAFFEINE CITRATE	inhibitor	Gene-targeted
CARBACHOL	None	Gene-targeted
CARVEDILOL	inhibitor	Gene-targeted
CARVEDILOL PHOSPHATE	inhibitor	Gene-targeted
CELIPROLOL	inhibitor	Gene-targeted
CHLORPROMAZINE	inhibitor	Gene-targeted
CICLESONIDE	None	Direct
CIPROFLOXACIN	None	Gene-targeted
CLOMIPRAMINE	inhibitor	Gene-targeted
CLOMIPRAMINE	None	Gene-targeted
CLONIDINE HYDROCHLORIDE	agonist; agonist	Gene-targeted
CLOZAPINE	inhibitor	Gene-targeted
CORTISONE ACETATE	None	Direct
CROMOLYN SODIUM	None	Direct
CYPROHEPTADINE HYDROCHLORIDE	inhibitor	Gene-targeted
DAPIPRAZOLE	inhibitor	Gene-targeted
DAPIPRAZOLE HYDROCHLORIDE	inhibitor	Gene-targeted
DEBRISOQUIN		Gene-targeted
DEFIBROTIDE	agonist	Gene-targeted
DEXAMETHASONE	None	Direct
DEXAMETHASONE SODIUM PHOSPHATE	None	Direct
DEXMEDETOMIDINE HYDROCHLORIDE	agonist	Gene-targeted
DEXTROAMPHETAMINE SULFATE		Gene-targeted
DIAZEPAM	None	Gene-targeted
DICHLORPHENAMIDE	None	Gene-targeted
DIETHYLSTILBESTROL	None	Gene-targeted
DIPIVEFRIN		Gene-targeted
DIPIVEFRIN HYDROCHLORIDE	agonist	Gene-targeted
DISULFIRAM		Gene-targeted
DOPAMINE		Gene-targeted
DOXAZOSIN MESYLATE	inhibitor	Gene-targeted
DOXAZOSIN MESYLATE	inhibitor	Gene-targeted
DRONEDARONE		Gene-targeted
DROXIDOPA	agonist	Gene-targeted
EPHEDRINE		Gene-targeted
EPHEDRINE HYDROCHLORIDE	agonist	Gene-targeted
EPHEDRINE SULFATE	agonist	Gene-targeted
EPHEDRINE SULFATE	None	Direct
EPINEPHRINE	agonist; agonist	Gene-targeted
EPINEPHRINE	None	Direct
EPINEPHRINE BITARTRATE	agonist	Gene-targeted
EPIRUBICIN	None	Gene-targeted
ERGOLOID MESYLATES	inhibitor	Gene-targeted
ERGOLOID MESYLATES, USP		Gene-targeted
ERGOTAMINE		Gene-targeted
ERGOTAMINE TARTRATE	agonist	Gene-targeted
ETHOXZOLAMIDE	None	Gene-targeted
ETOMIDATE		Gene-targeted
FENOLDOPAM		Gene-targeted
FLAVONE	inhibitor	Gene-targeted
FLUMAZENIL	None	Gene-targeted
FLUNISOLIDE	None	Direct
FLUTICASONE PROPIONATE	None	Direct
FORMOTEROL FUMARATE	None	Direct
GUANABENZ	agonist	Gene-targeted
GUANABENZ ACETATE	agonist	Gene-targeted
GUANFACINE HYDROCHLORIDE	agonist	Gene-targeted
GUANFACINE HYDROCHLORIDE	agonist	Gene-targeted
HYDROCORTISONE	None	Direct
HYDROXYAMPHETAMINE HYDROBROMIDE	agonist	Gene-targeted
ILOPERIDONE		Gene-targeted
IMIPRAMINE	None	Gene-targeted
INDAPAMIDE	None	Gene-targeted
INDOMETHACIN	None	Gene-targeted
ISOPROTERENOL		Gene-targeted
ISOSORBIDE DINITRATE	None	Gene-targeted
ISTRADEFYLLINE	inhibitor; inhibitor	Gene-targeted
LABETALOL	inhibitor	Gene-targeted
LABETALOL HYDROCHLORIDE	inhibitor	Gene-targeted
LEVODOPA		Gene-targeted
LEVONORDEFRIN	agonist	Gene-targeted
LISDEXAMFETAMINE DIMESYLATE		Gene-targeted
LOFEXIDINE	agonist	Gene-targeted
LOFEXIDINE HYDROCHLORIDE	agonist	Gene-targeted
LURASIDONE HYDROCHLORIDE	inhibitor	Gene-targeted
MAFENIDE	None	Gene-targeted
MECAMYLAMINE	None	Gene-targeted
MEFLOQUINE	inhibitor	Gene-targeted
MENTHOL	None	Direct
MEPERIDINE HYDROCHLORIDE		Gene-targeted
MEPHENTERMINE		Gene-targeted
MEPHENTERMINE SULFATE	agonist	Gene-targeted
METARAMINOL		Gene-targeted
METARAMINOL BITARTRATE	agonist	Gene-targeted
METHAMPHETAMINE		Gene-targeted
METHAZOLAMIDE	None	Gene-targeted
METHOTRIMEPRAZINE		Gene-targeted
METHOXAMINE	agonist	Gene-targeted
METHOXAMINE HYDROCHLORIDE	agonist	Gene-targeted
METHOXSALEN	None	Gene-targeted
METHYLDOPA ANHYDROUS	agonist	Gene-targeted
METHYLDOPATE HYDROCHLORIDE	agonist	Gene-targeted
METHYLPREDNISOLONE	None	Direct
METHYLPREDNISOLONE ACETATE	None	Direct
METHYLPREDNISOLONE SODIUM SUCCINATE	None	Direct
METOPROLOL	None	Gene-targeted
METOPROLOL SUCCINATE		Gene-targeted
MIANSERIN	None	Gene-targeted
MIDODRINE		Gene-targeted
MIDODRINE HYDROCHLORIDE	agonist	Gene-targeted
MILNACIPRAN		Gene-targeted
MIRTAZAPINE	inhibitor; inhibitor	Gene-targeted
MODAFINIL		Gene-targeted
MOMETASONE FUROATE	None	Direct
MONTELUKAST SODIUM	None	Direct
MOXISYLYTE	inhibitor	Gene-targeted
MOXONIDINE	agonist	Gene-targeted
NAFTOPIDIL	inhibitor	Gene-targeted
NALIDIXIC ACID	None	Gene-targeted
NAPHAZOLINE	agonist	Gene-targeted
NAPHAZOLINE HYDROCHLORIDE	agonist	Gene-targeted
NEFAZODONE		Gene-targeted
NICARDIPINE	inhibitor	Gene-targeted
NICOTINE	None	Gene-targeted
NIFEDIPINE		Gene-targeted
NOREPINEPHRINE	agonist	Gene-targeted
NOREPINEPHRINE BITARTRATE	agonist	Gene-targeted
NORFLOXACIN	None	Gene-targeted
NORTRIPTYLINE	inhibitor	Gene-targeted
OFLOXACIN	None	Gene-targeted
OLANZAPINE		Gene-targeted
OXTRIPHYLLINE	inhibitor	Gene-targeted
OXYMETAZOLINE HYDROCHLORIDE	agonist	Gene-targeted
OXYMETAZOLINE HYDROCHLORIDE	agonist	Gene-targeted
PAPAVERINE		Gene-targeted
PENTOXIFYLLINE	inhibitor	Gene-targeted
PERGOLIDE	agonist	Gene-targeted
PHENDIMETRAZINE		Gene-targeted
PHENOXYBENZAMINE	inhibitor	Gene-targeted
PHENOXYBENZAMINE HYDROCHLORIDE	inhibitor	Gene-targeted
PHENTOLAMINE	inhibitor	Gene-targeted
PHENTOLAMINE MESYLATE	inhibitor	Gene-targeted
PHENYLEPHRINE	agonist	Gene-targeted
PHENYLEPHRINE BITARTRATE	agonist	Gene-targeted
PHENYLEPHRINE HYDROCHLORIDE	agonist	Gene-targeted
PHENYLPROPANOLAMINE		Gene-targeted
PHENYLPROPANOLAMINE HYDROCHLORIDE	agonist	Gene-targeted
PHENYLPROPANOLAMINE POLISTIREX	agonist	Gene-targeted
PHENYTOIN	None	Gene-targeted
PIRBUTEROL ACETATE	None	Direct
PRAZOSIN	inhibitor	Gene-targeted
PRAZOSIN	None	Gene-targeted
PRAZOSIN HYDROCHLORIDE	inhibitor	Gene-targeted
PREDNISOLONE SODIUM PHOSPHATE	None	Direct
PREDNISONE	None	Direct
PROMAZINE		Gene-targeted
PROPIOMAZINE		Gene-targeted
PSEUDOEPHEDRINE POLISTIREX		Gene-targeted
QUETIAPINE FUMARATE		Gene-targeted
RACEPINEPHRINE	agonist	Gene-targeted
RAUWOLFIA SERPENTINA	inhibitor	Gene-targeted
RAUWOLFIA SERPENTINA (USP)	inhibitor	Gene-targeted
REGADENOSON	agonist	Gene-targeted
REGADENOSON ANHYDROUS	agonist	Gene-targeted
REMIFENTANIL HYDROCHLORIDE		Gene-targeted
RISPERIDONE	inhibitor	Gene-targeted
SALMETEROL XINAFOATE	None	Direct
SERTINDOLE	inhibitor	Gene-targeted
SILODOSIN	inhibitor	Gene-targeted
SIROLIMUS	None	Gene-targeted
SODIUM CHLORIDE		Gene-targeted
SULBACTAM	None	Gene-targeted
TACROLIMUS ANHYDROUS	None	Gene-targeted
TAMSULOSIN HYDROCHLORIDE	inhibitor	Gene-targeted
TAMSULOSIN HYDROCHLORIDE	inhibitor	Gene-targeted
TAZOBACTAM	None	Gene-targeted
TERAZOSIN	inhibitor	Gene-targeted
TERAZOSIN HYDROCHLORIDE	inhibitor	Gene-targeted
TETRAHYDROZOLINE HYDROCHLORIDE	agonist	Gene-targeted
THEOPHYLLINE	inhibitor	Gene-targeted
THEOPHYLLINE	inhibitor	Gene-targeted
THEOPHYLLINE SODIUM GLYCINATE	inhibitor	Gene-targeted
THIORIDAZINE		Gene-targeted
TIOTROPIUM BROMIDE	None	Direct
TIZANIDINE HYDROCHLORIDE	agonist	Gene-targeted
TIZANIDINE HYDROCHLORIDE	agonist	Gene-targeted
TOLAZOLINE	inhibitor	Gene-targeted
TOLAZOLINE HYDROCHLORIDE	inhibitor	Gene-targeted
TRAZODONE		Gene-targeted
TRIFLUOPERAZINE		Gene-targeted
TRIMIPRAMINE MALEATE	inhibitor	Gene-targeted
TROGLITAZONE	None	Gene-targeted
VIDARABINE		Gene-targeted
VILANTEROL TRIFENATATE	None	Direct
XYLAZINE	agonist	Gene-targeted
XYLOMETAZOLINE	agonist	Gene-targeted
XYLOMETAZOLINE HYDROCHLORIDE	agonist	Gene-targeted
YOHIMBINE	inhibitor	Gene-targeted
ZAFIRLUKAST	None	Direct
ZIPRASIDONE		Gene-targeted

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, and merged ranking. Only agents with registry trials or published clinical literature are shown by default.

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ALBUTEROL SULFATE	Small molecule	Approved	Strong	100	8 trials 18 Trial pubs 16 RCT View evidence Registry trials NCT02126839 — A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics (COMPLETED) PHASE3 NCT02479412 — A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma (COMPLETED) PHASE2 NCT00529529 — Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma (COMPLETED) PHASE3 NCT00667407 — Efficacy and Safety of Levalbuterol Versus Racemic Albuterol in Asthma (COMPLETED) PHASE3 NCT00200967 — Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE) (COMPLETED) PHASE3 NCT00096616 — Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma (COMPLETED) PHASE2 NCT01302587 — A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI) (COMPLETED) NCT02794519 — A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma (WITHDRAWN) PHASE2 Published literature Clinical trial publication Dose-Ranging and Cumulative Dose Studies of Albuterol Sulfate MDI in Co-Suspension Delivery™ Technology (AS MDI; PT007) in Patients with Asthma: the ASPEN and ANTORA Trials (Clinical drug investigation, 2021) Clinical trial publication Effect of heliox- and air-driven nebulized bronchodilator therapy on lung function in patients with asthma (Lung, 2014) Clinical trial publication Prospective, open-label assessment of albuterol sulfate hydrofluoroalkane metered-dose inhaler with new integrated dose counter (Allergy and asthma proceedings, 2013) Clinical trial publication The effect of heliox-driven bronchodilator aerosol therapy on pulmonary function tests in patients with asthma (The Journal of asthma : official journal of the Association for the Care of Asthma, 2002) Clinical trial publication Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial (JAMA, 2001) Randomized controlled trial Clinical comparability of ventolin formulated with hydrofluoroalkane or conventional chlorofluorocarbon propellants in children with asthma (Archives of pediatrics & adolescent medicine, 2000) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
AMINOPHYLLINE	Biologic	Approved	Strong	100	3 trials 11 Cochrane 7 Meta-analysis 156 Trial pubs 98 RCT View evidence Registry trials NCT00442338 — Study of MK-0476 in Adult Patients With Acute Asthma (0476-334) (COMPLETED) PHASE3 NCT03296579 — Non-invasive Ventilation vs. Standard Therapy for Children Hospitalized With an Acute Exacerbation of Asthma (UNKNOWN) NA NCT02270827 — A Pilot Study Into Health Pre and Post Treatment With Intravenous Aminophylline and Hydrocortisone in Severe Asthmatics (TERMINATED) Published literature Cochrane review Use of intravenous aminophylline in addition to the standard first-line treatment in children and adolescents with an acute asthma exacerbation: a systematic review and meta-analysis of randomised controlled trials (Archives of disease in childhood, 2025) Cochrane review Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews (The Cochrane database of systematic reviews, 2020) Cochrane review Guideline on management of the acute asthma attack in children by Italian Society of Pediatrics (Italian journal of pediatrics, 2018) Cochrane review Efficacy and side effects of intravenous theophylline in acute asthma: a systematic review and meta-analysis (Drug design, development and therapy, 2018) Cochrane review Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma (The Cochrane database of systematic reviews, 2012) Meta-analysis Intravenous Bronchodilators in Pediatric Critical Asthma: A Systematic Review and Network Meta-Analysis (Pediatric pulmonology, 2025) Meta-analysis Second-line treatment option for children aged 18 years and under with an acute severe asthma exacerbation: a systematic review and meta-analysis of randomised controlled trials (Archives of disease in childhood, 2025) Systematic review Use of ketamine in patients with refractory severe asthma exacerbations: systematic review of prospective studies (European journal of clinical pharmacology, 2022) Clinical trial publication Magnesium sulfate vs aminophylline as a second line of treatment in children with severe acute asthma. Randomized clinical trial (Andes pediatrica : revista Chilena de pediatria, 2021) Clinical trial publication Randomised comparison of intravenous magnesium sulphate, terbutaline and aminophylline for children with acute severe asthma (Acta paediatrica (Oslo, Norway : 1992), 2014) Clinical trial publication [Clinical efficacies of inhaled corticosteroids plus theophylline in the treatment of bronchial asthma] (Zhonghua yi xue za zhi, 2013) Clinical trial publication The efficacy and tolerability of intravenous montelukast in acute asthma exacerbations in Japanese patients (The Journal of asthma : official journal of the Association for the Care of Asthma, 2012) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
BECLOMETHASONE DIPROPIONATE	Small molecule	Approved	Strong	100	8 trials 18 Cochrane 21 Meta-analysis 541 Trial pubs 388 RCT View evidence Registry trials NCT04886999 — Study in Adult Patients With Moderate to Severe Asthma (COMPLETED) PHASE3 NCT01345916 — Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients (COMPLETED) PHASE3 NCT00200967 — Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE) (COMPLETED) PHASE3 NCT00094016 — Evaluation of Two Doses of QVAR by Breath Operated and Metered Dose Inhalers in Asthmatic Children (COMPLETED) PHASE3 NCT01520688 — Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth (COMPLETED) PHASE4 NCT01141439 — Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management (COMPLETED) NCT01287351 — Real-world Effectiveness and Cost-effectiveness of Qvar Versus FP, a US Study (COMPLETED) NCT00497237 — Clinical Trial of the Efficacy and Safety of Beclomethasone Dipropionate Plus Formoterol vs Fluticasone Propionate Plus Salmeterol in the 6 Months Step Down Treatment of Asthma (COMPLETED) PHASE3 Published literature Cochrane review Inhaled corticosteroids in children with persistent asthma: effects on growth (The Cochrane database of systematic reviews, 2014) Cochrane review Omalizumab for asthma in adults and children (The Cochrane database of systematic reviews, 2014) Cochrane review Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children (The Cochrane database of systematic reviews, 2010) Cochrane review Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children (The Cochrane database of systematic reviews, 2010) Cochrane review Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children (The Cochrane database of systematic reviews, 2007) Meta-analysis Adrenal suppression by inhaled corticosteroids in patients with asthma: A systematic review and quantitative analysis (Allergy and asthma proceedings, 2016) Systematic review Efficacy and safety of inhaled corticosteroids relative to fluticasone propionate: a systematic review of randomized controlled trials in asthma (Expert review of respiratory medicine, 2017) Systematic review Principal findings of systematic reviews for chronic treatment in childhood asthma (The Journal of asthma : official journal of the Association for the Care of Asthma, 2015) Clinical trial publication [Efficacy and safety of inhaled salbutamol sulfate combined with beclomethasone dipropionate in children with bronchial asthma: a randomized controlled study] (Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2025) Clinical trial publication Improved lung function with beclomethasone/formoterol versus beclomethasone alone in asthma: the FORCE2 study (The Journal of asthma : official journal of the Association for the Care of Asthma, 2026) Clinical trial publication Evaluating the impact of changing inhaler color on perception of symptoms and disease burden in patients with asthma: the FEEL study (The Journal of asthma : official journal of the Association for the Care of Asthma, 2025) Clinical trial publication Comparison of extrafine beclomethasone dipropionate/formoterol fumarate dry powder inhaler and pressurized metered-dose inhaler in Chinese patients with asthma: the FORTUNE study (The Journal of asthma : official journal of the Association for the Care of Asthma, 2024) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
BETAMETHASONE ACETATE	Small molecule	Approved	Strong	100	No indexed hits View evidence CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
BUDESONIDE	Small molecule	Approved	Strong	100	8 trials 57 Cochrane 66 Meta-analysis 910 Trial pubs 793 RCT View evidence Registry trials NCT04609904 — Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS) (COMPLETED) PHASE3 NCT00235911 — Symbicort Single Inhaler Therapy for Asthma in a General Practice Setting (COMPLETED) PHASE3 NCT03788057 — Inflammatory Indices in Predicting the Failure of Inhaled Corticosteroids Reduction in Young Participants With Asthma (COMPLETED) NA NCT01520688 — Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth (COMPLETED) PHASE4 NCT01444430 — A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents (COMPLETED) PHASE3 NCT06080945 — Tailored Pharmacist-led Intervention to Improve Adherence to Budesonide (UNKNOWN) NA NCT00641446 — Varicella Vaccination With Pulmicort (COMPLETED) PHASE4 NCT03319043 — Observation of Cough Variant Asthma Treated in Combination of Chanqin Granules. (UNKNOWN) PHASE1, PHASE2 Published literature Cochrane review Adverse events of inhaled corticosteroids in adult patients with asthma or chronic obstructive pulmonary disease: pairwise, network and dose-response meta-analyses (BMJ evidence-based medicine, 2026) Cochrane review Efficacy and safety profile of doxofylline in asthma: a meta-analysis (The Journal of asthma : official journal of the Association for the Care of Asthma, 2025) Cochrane review Single maintenance and reliever therapy in treatment of asthma exacerbations (Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2022) Cochrane review A review of the efficacy and safety of fluticasone propionate/formoterol fixed-dose combination (Expert review of respiratory medicine, 2022) Cochrane review Combination fixed-dose β agonist and steroid inhaler as required for adults or children with mild asthma: a Cochrane systematic review (BMJ evidence-based medicine, 2022) Meta-analysis Effect of aerosol inhalation of budesonide on respiratory symptoms and inflammatory factors in patients with asthma: a meta-analysis (The Journal of asthma : official journal of the Association for the Care of Asthma, 2024) Meta-analysis Clinical efficacy of montelukast sodium combination therapy for cough variant asthma in children: A meta-analysis (Pediatric pulmonology, 2024) Meta-analysis Effect of Montelukast Combined with Budesonide on Inflammatory Response and Pulmonary Function in Children with Cough Variant Asthma: A Meta-analysis (Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2023) Systematic review [IS AS NEEDED THERAPY WITH AN INHALED BUDESONIDE/FORMOTEROL COMBINATION ONLY WHEN SYMPTOMATIC AS AN OPTION IN THE MANAGEMENT OF PATIENTS WITH MILD ASTHMA?] (Arerugi = [Allergy], 2025) Systematic review Quantitative comparison of different inhaled corticosteroids in the treatment of asthma in children (Pediatric research, 2023) Clinical trial publication Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials (The Lancet. Respiratory medicine, 2026) Clinical trial publication Analysis of risk factors for recurrence in children with asthmatic bronchopneumonia during remission and discussion on the therapeutic effect of diprophylline combined with budesonide (Pakistan journal of pharmaceutical sciences, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
CICLESONIDE	Small molecule	Approved	Strong	100	8 trials 9 Cochrane 10 Meta-analysis 77 Trial pubs 74 RCT View evidence Registry trials NCT00163371 — Effects of Inhaled Ciclesonide Versus Fluticasone Propionate Versus Placebo on Lower Leg Growth in Prepubertal Children With Mild Persistent Asthma (6 to 12 y) (BY9010/M1-208) (COMPLETED) PHASE3 NCT01455194 — Effect of High Dose Ciclesonide on Asthma Control (COMPLETED) PHASE3 NCT00163397 — Efficacy of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 y) (BY9010/M1-137) (COMPLETED) PHASE3 NCT06272370 — Individualizing Treatment for Asthma in Primary Care (COMPLETED) PHASE4 NCT03839433 — The Mannitol-Asthma-Ciclesonide-Study (COMPLETED) PHASE4 NCT00174733 — Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid (COMPLETED) PHASE3 NCT00525772 — Effect of Ciclesonide on Exercise Induced Bronchoconstriction (COMPLETED) PHASE3 NCT00163293 — Efficacy of Ciclesonide Inhaled Once Daily Versus Other Corticosteroids Used for Treatment of Mild Asthma in Children (4 to 11 Years) (BY9010/CA-101) (COMPLETED) PHASE3 Published literature Cochrane review Adverse events of inhaled corticosteroids in adult patients with asthma or chronic obstructive pulmonary disease: pairwise, network and dose-response meta-analyses (BMJ evidence-based medicine, 2026) Cochrane review Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids (The Cochrane database of systematic reviews, 2015) Cochrane review Inhaled corticosteroids in children with persistent asthma: dose-response effects on growth (The Cochrane database of systematic reviews, 2014) Cochrane review Inhaled corticosteroids in children with persistent asthma: effects on growth (The Cochrane database of systematic reviews, 2014) Cochrane review Ciclesonide: long-term treatment of persistent asthma--no clear progress (Prescrire international, 2013) Meta-analysis Inhaled ciclesonide for outpatients with COVID-19: A meta-analysis (Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2022) Meta-analysis Extrafine Versus Fine Inhaled Corticosteroids in Relation to Asthma Control: A Systematic Review and Meta-Analysis of Observational Real-Life Studies (The journal of allergy and clinical immunology. In practice, 2018) Meta-analysis Adrenal suppression by inhaled corticosteroids in patients with asthma: A systematic review and quantitative analysis (Allergy and asthma proceedings, 2016) Systematic review Local and systemic adverse effects of inhaled corticosteroids - Does ciclesonide differ from other inhaled corticosteroids? (Respiratory medicine, 2025) Systematic review Quantitative comparison of different inhaled corticosteroids in the treatment of asthma in children (Pediatric research, 2023) Systematic review Efficacy and safety of inhaled corticosteroids relative to fluticasone propionate: a systematic review of randomized controlled trials in asthma (Expert review of respiratory medicine, 2017) Clinical trial publication Inhaled ciclesonide does not affect production of antibodies or elimination of virus in patients with COVID-19: Subanalysis of a multicenter, open-label randomized trial (Drug discoveries & therapeutics, 2023) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
CORTISONE ACETATE	Small molecule	Approved	Strong	100	—	Open Targets, ChEMBL	ChEMBL Open Targets
CROMOLYN SODIUM	Small molecule	Approved	Strong	100	3 trials 1 Cochrane 111 Trial pubs 61 RCT View evidence Registry trials NCT01346852 — Predictive Ability of Therapeutic Risk Factors in Pediatric and Adult Asthma Patients (COMPLETED) NCT00943397 — Extended Safety Study of Montelukast in Infants and Young Children With Chronic Asthma (0476-232) (COMPLETED) PHASE3 NCT06535087 — The Impact of Airway Allergic Diseases on Children's and Parents' Quality of Life (RECRUITING) Published literature Cochrane review Asthma controller therapy during pregnancy (American journal of obstetrics and gynecology, 2005) Systematic review Nebulized Inhaled Corticosteroids in Asthma Treatment in Children 5 Years or Younger: A Systematic Review and Global Expert Analysis (The journal of allergy and clinical immunology. In practice, 2020) Clinical trial publication Salivary cortisol monitoring: determination of reference values in healthy children and application in asthmatic children (Allergy and asthma proceedings, 2012) Clinical trial publication [Effects of acupuncture on the pulmonary function and heart rate variability in different state of bronchial asthma] (Zhen ci yan jiu = Acupuncture research, 2007) Clinical trial publication [Lung functioning changes of asthmatic adults in treatment with cromolyn sodium and beclomethasone] (Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993), 2004) Clinical trial publication Evaluation of parental preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: a randomized, open-label, crossover study (The Journal of asthma : official journal of the Association for the Care of Asthma, 2003) Clinical trial publication Effects of budesonide inhalation suspension compared with cromolyn sodium nebulizer solution on health status and caregiver quality of life in childhood asthma (Pediatrics, 2003) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
DEXAMETHASONE	Small molecule	Approved	Strong	100	8 trials 7 Cochrane 11 Meta-analysis 60 Trial pubs 39 RCT View evidence Registry trials NCT03133897 — Dexamethasone Versus Prednisone for Asthma Treatment in the Pediatric Inpatient Population; a Feasibility Study (TERMINATED) PHASE3 NCT01326494 — Reducing the Acute Care Burden of Childhood Asthma on Health Services in British Columbia (COMPLETED) PHASE4 NCT05850143 — EFFECTIVENESS OF SINGLE DOSE ORAL DEXAMETHASONE VERSUS MULTIDOSE PREDNISOLONE FOR TREATMENT OF ACUTE EXACERBATIONS OF ASTHMA AMONG CHILDREN ATTENDING THE EMERGENCY DEPARTMENT OF CHILDREN HOSPITAL, ISLAMABAD (UNKNOWN) NA NCT07228052 — Giving Asthmatics Intramuscular Steroids for Preventing Return to the Emergency Department (NOT_YET_RECRUITING) PHASE4 NCT00942201 — Comparison of Oral Dexamethasone Doses in Asthma Exacerbation (COMPLETED) NA NCT02725008 — Trial of One Versus Two Doses of Dexamethasone for Pediatric Asthma Exacerbation (COMPLETED) PHASE3 NCT04278404 — Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (RECRUITING) NCT03900624 — Ideal Steroids for Asthma Treatment in the PICU (COMPLETED) PHASE4 Published literature Cochrane review The efficacy of dexamethasone compared to prednisone/prednisolone for the management of pediatric patients with acute exacerbation of asthma: a systematic review and meta-analysis (The Journal of asthma : official journal of the Association for the Care of Asthma, 2025) Cochrane review Dexamethasone versus prednisone/prednisolone in the management of pediatric patients with acute asthmatic exacerbations: a systematic review and meta-analysis (The Journal of asthma : official journal of the Association for the Care of Asthma, 2023) Cochrane review Safety of corticosteroids in young children with acute respiratory conditions: a systematic review and meta-analysis (BMJ open, 2019) Cochrane review Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for acute asthma (The Cochrane database of systematic reviews, 2018) Cochrane review Different oral corticosteroid regimens for acute asthma (The Cochrane database of systematic reviews, 2016) Meta-analysis Oral systemic corticosteroids in children with acute asthma exacerbations: a systematic review and network meta-analysis (Archives of disease in childhood, 2025) Meta-analysis Dexamethasone Versus Prednisone or Prednisolone for Acute Pediatric Asthma Exacerbations in the Emergency Department: A Meta-Analysis (Pediatric emergency care, 2021) Clinical trial publication Circulating miRNAs and childhood asthma ICS response: a stratified analysis in the intervention arm of an RCT with vitamin D effect modification (Thorax, 2025) Clinical trial publication Dexamethasone versus methylprednisolone for critical asthma: A single center, open-label, parallel-group clinical trial (Pediatric pulmonology, 2023) Clinical trial publication Single-Dose Dexamethasone Is Not Inferior to 2 Doses in Mild to Moderate Pediatric Asthma Exacerbations in the Emergency Department (Pediatric emergency care, 2022) Clinical trial publication A Randomized Controlled Study Addressing Dexamethasone Tolerability in the Treatment of Acute Asthma in Children: Mary Poppins on Trial! (Journal of pharmacy practice, 2023) Clinical trial publication Dexamethasone-Induced FKBP51 Expression in CD4(+) T-Lymphocytes Is Uniquely Associated With Worse Asthma Control in Obese Children With Asthma (Frontiers in immunology, 2021) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
DEXAMETHASONE SODIUM PHOSPHATE	Small molecule	Approved	Strong	100	8 trials View evidence Registry trials NCT03133897 — Dexamethasone Versus Prednisone for Asthma Treatment in the Pediatric Inpatient Population; a Feasibility Study (TERMINATED) PHASE3 NCT01326494 — Reducing the Acute Care Burden of Childhood Asthma on Health Services in British Columbia (COMPLETED) PHASE4 NCT05850143 — EFFECTIVENESS OF SINGLE DOSE ORAL DEXAMETHASONE VERSUS MULTIDOSE PREDNISOLONE FOR TREATMENT OF ACUTE EXACERBATIONS OF ASTHMA AMONG CHILDREN ATTENDING THE EMERGENCY DEPARTMENT OF CHILDREN HOSPITAL, ISLAMABAD (UNKNOWN) NA NCT07228052 — Giving Asthmatics Intramuscular Steroids for Preventing Return to the Emergency Department (NOT_YET_RECRUITING) PHASE4 NCT00942201 — Comparison of Oral Dexamethasone Doses in Asthma Exacerbation (COMPLETED) NA NCT02725008 — Trial of One Versus Two Doses of Dexamethasone for Pediatric Asthma Exacerbation (COMPLETED) PHASE3 NCT04278404 — Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (RECRUITING) NCT03900624 — Ideal Steroids for Asthma Treatment in the PICU (COMPLETED) PHASE4 CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
EPHEDRINE SULFATE	Small molecule	Approved	Strong	100	4 Trial pubs 1 RCT View evidence Published literature Clinical trial publication A comparative study of bronchodilator effects of carbuterol and ephedrine (JAMA, 1979) Clinical trial publication Double-blind trial of oral carbuterol in bronchial asthma (Annals of allergy, 1977) Clinical trial publication Ephedrine therapy in asthmatic children. Clinical tolerance and absence of side effects (JAMA, 1977) Clinical trial publication Subsensitivity to epinephrine following the administration of epinephrine and ephedrine to normal individuals (The Journal of allergy and clinical immunology, 1975) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
EPINEPHRINE	Small molecule	Approved	Strong	100	—	Open Targets, ChEMBL	ChEMBL Open Targets
FLUNISOLIDE	Small molecule	Approved	Strong	100	3 trials 4 Cochrane 6 Meta-analysis 53 Trial pubs 41 RCT View evidence Registry trials NCT02404103 — Flunisolide HFA in Children With Small Airway Disease (COMPLETED) NA NCT00203684 — Mentored Patient-Oriented Research Career Development Award (COMPLETED) PHASE1 NCT01347060 — Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy (COMPLETED) Published literature Cochrane review Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations (Journal of aerosol medicine and pulmonary drug delivery, 2016) Cochrane review Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids (The Cochrane database of systematic reviews, 2015) Cochrane review Inhaled corticosteroids in children with persistent asthma: effects on growth (The Cochrane database of systematic reviews, 2014) Cochrane review Effectiveness of inhaled corticosteroids in the treatment of acute asthma in children in the emergency department: a meta-analysis (Annals of medicine, 2014) Meta-analysis Relative oral corticosteroid-sparing effect of 7 inhaled corticosteroids in chronic asthma: a meta-analysis (Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2008) Meta-analysis Meta-analysis finds use of inhaled corticosteroids during pregnancy safe: a systematic meta-analysis review (Human & experimental toxicology, 2006) Meta-analysis Improved asthma control after changing from low-to-medium doses of other inhaled corticosteroids to low-dose fluticasone propionate (MedGenMed : Medscape general medicine, 2001) Systematic review Inhaled versus systemic corticosteroids for acute asthma in children. A systematic review (Pediatric pulmonology, 2014) Clinical trial publication Linear growth and bone maturation are unaffected by 1 year of therapy with inhaled flunisolide hydrofluoroalkane in prepubescent children with mild persistent asthma: a randomized, double-blind, placebo-controlled trial (Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2011) Clinical trial publication High-dose inhaled flunisolide versus budesonide in the treatment of acute asthma exacerbations in preschool-age children (International journal of immunopathology and pharmacology, 2009) Clinical trial publication Flunisolide decreases exhaled nitric oxide and nitrotyrosine levels in asthmatic children (Mediators of inflammation, 2006) Clinical trial publication Effects of long-term inhaled corticosteroids on adrenal function in patients with asthma (Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2006) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
FLUTICASONE PROPIONATE	Small molecule	Approved	Strong	100	8 trials 22 Cochrane 40 Meta-analysis 572 Trial pubs 501 RCT View evidence Registry trials NCT02388373 — A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down (COMPLETED) PHASE4 NCT01669070 — A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI) (COMPLETED) PHASE1 NCT01165138 — Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics (COMPLETED) PHASE3 NCT00163371 — Effects of Inhaled Ciclesonide Versus Fluticasone Propionate Versus Placebo on Lower Leg Growth in Prepubertal Children With Mild Persistent Asthma (6 to 12 y) (BY9010/M1-208) (COMPLETED) PHASE3 NCT01520688 — Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth (COMPLETED) PHASE4 NCT00400855 — Study on the Effects of an AMP Challenge on Asthmatic Patients Following Treatment With Fluticasone Propionate (COMPLETED) PHASE2 NCT01141439 — Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management (COMPLETED) NCT01516073 — 12-Week Study in Adult Subjects With Asthma (COMPLETED) PHASE2 Published literature Cochrane review A review of the efficacy and safety of fluticasone propionate/formoterol fixed-dose combination (Expert review of respiratory medicine, 2022) Cochrane review The efficacy and safety of fluticasone propionate/formoterol compared with fluticasone propionate/salmeterol in treating pediatric asthma: a systematic review and meta-analysis (The Journal of international medical research, 2020) Cochrane review Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations (Journal of aerosol medicine and pulmonary drug delivery, 2016) Cochrane review Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids (The Cochrane database of systematic reviews, 2015) Cochrane review Inhaled corticosteroids in children with persistent asthma: effects on growth (The Cochrane database of systematic reviews, 2014) Meta-analysis Clinical efficacy of montelukast sodium combination therapy for cough variant asthma in children: A meta-analysis (Pediatric pulmonology, 2024) Meta-analysis An efficacy and safety evaluation of montelukast + fluticasone propionate vs. fluticasone propionate in the treatment of cough variant asthma in children: a meta-analysis (BMC pulmonary medicine, 2023) Meta-analysis Efficacy and safety of fluticasone propionate/salmeterol and fluticasone propionate monotherapy in step-up treatment of childhood asthma: A systematic review and meta-analysis (Heart & lung : the journal of critical care, 2024) Meta-analysis Impact of inhaled fluticasone propionate/salmeterol on health-related quality of life in asthma: A network meta-analysis (Respiratory medicine, 2022) Meta-analysis Quantitative comparison of dose-effect and time-course of fluticasone furoate and fluticasone propionate in adult and adolescent patients with persistent asthma: A systematic review and meta-analysis (Respirology (Carlton, Vic.), 2022) Systematic review Local and systemic adverse effects of inhaled corticosteroids - Does ciclesonide differ from other inhaled corticosteroids? (Respiratory medicine, 2025) Systematic review Exploring the Relationship between Inhaled Corticosteroid Usage, Asthma Severity, and Sleep-Disordered Breathing: A Systematic Literature Review (Advances in respiratory medicine, 2024) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
FORMOTEROL FUMARATE	Small molecule	Approved	Strong	100	8 trials 6 Cochrane 7 Meta-analysis 58 Trial pubs 53 RCT View evidence Registry trials NCT02388373 — A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down (COMPLETED) PHASE4 NCT04886999 — Study in Adult Patients With Moderate to Severe Asthma (COMPLETED) PHASE3 NCT04609904 — Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS) (COMPLETED) PHASE3 NCT00235911 — Symbicort Single Inhaler Therapy for Asthma in a General Practice Setting (COMPLETED) PHASE3 NCT00746330 — Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma (COMPLETED) PHASE2 NCT01444430 — A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents (COMPLETED) PHASE3 NCT01711086 — Safety and Efficacy of the Inspiromatic Inhaler in Comparison to the Aerolizer Inhaler When Delivering Formoterol (UNKNOWN) PHASE1, PHASE2 NCT03319043 — Observation of Cough Variant Asthma Treated in Combination of Chanqin Granules. (UNKNOWN) PHASE1, PHASE2 Published literature Cochrane review A review of the efficacy and safety of fluticasone propionate/formoterol fixed-dose combination (Expert review of respiratory medicine, 2022) Cochrane review Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations (Journal of aerosol medicine and pulmonary drug delivery, 2016) Cochrane review Formoterol for acute asthma in the emergency department: a systematic review with meta-analysis (Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2010) Cochrane review Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid (The Cochrane database of systematic reviews, 2007) Cochrane review Inhaled long acting beta agonists for stable chronic asthma (The Cochrane database of systematic reviews, 2003) Meta-analysis Appraisal of lens opacity with mometasone furoate/formoterol fumarate combination in patients with COPD or asthma (Respiratory medicine, 2014) Meta-analysis Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years (Health technology assessment (Winchester, England), 2008) Meta-analysis Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over (Health technology assessment (Winchester, England), 2008) Systematic review Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol (Clinical therapeutics, 2009) Clinical trial publication Safety and tolerability of the low global warming potential propellant HFA-152a in patients with asthma receiving beclometasone dipropionate/formoterol fumarate/glycopyrronium: The TRECOS study (Respiratory medicine, 2026) Clinical trial publication Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials (The Lancet. Respiratory medicine, 2026) Clinical trial publication Improved lung function with beclomethasone/formoterol versus beclomethasone alone in asthma: the FORCE2 study (The Journal of asthma : official journal of the Association for the Care of Asthma, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
HYDROCORTISONE	Small molecule	Approved	Strong	100	—	Open Targets, ChEMBL	ChEMBL Open Targets
INDOMETHACIN	Small molecule	Approved	Strong	100	1 trials 31 Trial pubs 18 RCT View evidence Registry trials NCT01733485 — Electrophilic Fatty Acid Derivatives in Asthma (COMPLETED) PHASE1 Published literature Clinical trial publication Effect of inhaled indomethacin in asthmatic patients taking high doses of inhaled corticosteroids (The Journal of allergy and clinical immunology, 2000) Clinical trial publication Allergen-induced synthesis of F(2)-isoprostanes in atopic asthmatics. Evidence for oxidant stress (American journal of respiratory and critical care medicine, 1999) Clinical trial publication Different effects of inhaled aspirinlike drugs on allergen-induced early and late asthmatic responses (American journal of respiratory and critical care medicine, 1999) Clinical trial publication Inhibitory effect of indomethacin on tachyphylaxis in response to acetaldehyde-induced bronchoconstriction in patients with asthma (The Journal of allergy and clinical immunology, 1997) Clinical trial publication Effect of inhaled frusemide and oral indomethacin on the airway response to hypertonic saline challenge in asthmatic subjects (Thorax, 1997) Randomized controlled trial Effect of inhaled indomethacin on exercise-induced bronchoconstriction in children with asthma (American journal of respiratory and critical care medicine, 1997) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
MENTHOL	Small molecule	Approved	Strong	100	1 trials 2 Trial pubs 2 RCT View evidence Registry trials NCT07500974 — Efficacy of L-menthol on Breathlessness in Asthma (NOT_YET_RECRUITING) PHASE2 Published literature Clinical trial publication Effect of menthol vapour on airway hyperresponsiveness in patients with mild asthma (Respiratory medicine, 1995) Clinical trial publication Comparative taste evaluation of aerosolized formulations of triamcinolone acetonide, flunisolide, and flunisolide with menthol (Clinical therapeutics, 1993) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
METHYLPREDNISOLONE	Small molecule	Approved	Strong	100	—	Open Targets, ChEMBL	ChEMBL Open Targets
METHYLPREDNISOLONE ACETATE	Small molecule	Approved	Strong	100	8 trials 2 Trial pubs 1 RCT View evidence Registry trials NCT04874610 — Steroid Metabolism in Obese and Non-Obese Pediatric Patients Hospitalized for Status Asthmaticus (COMPLETED) NCT06171932 — Comparison Of Efficacy Of Hydrocortisone And Methyl Prednisolone In Acute Severe Asthma (UNKNOWN) NCT00971893 — A Study To Assess The Safety And Effectiveness Of Medrol® In Acute Asthma In Indian Patients (WITHDRAWN) NCT03900624 — Ideal Steroids for Asthma Treatment in the PICU (COMPLETED) PHASE4 NCT07455396 — Pediatric Asthma Trial of Corticosteroid Heterogeneity (PATCH): Trial of Dexamethasone Versus Methylprednisolone for Pediatric Critical Asthma (NOT_YET_RECRUITING) PHASE2 NCT02872597 — Phase I, Placebo-Controlled, Blinded Pilot Study of Ipratropium in Children Admitted to the ICU With Status Asthmaticus (COMPLETED) PHASE1 NCT00576069 — Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma (RECRUITING) NCT00627731 — Oral Glucocorticosteroid in the Treatment of Severe Asthma Exacerbation in Hospitalized Patients (COMPLETED) PHASE4 Published literature Clinical trial publication Intramuscular methylprednisolone acetate for the prevention of relapse in acute asthma (Annals of emergency medicine, 1993) Clinical trial publication Comparison of preseasonal and coseasonal Allpyral with Depo-Medrone in summer hay-fever (British medical journal, 1969) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
METHYLPREDNISOLONE SODIUM SUCCINATE	Small molecule	Approved	Strong	100	—	Open Targets, ChEMBL	ChEMBL Open Targets
MOMETASONE FUROATE	Small molecule	Approved	Strong	100	8 trials 1 Cochrane 5 Meta-analysis 73 Trial pubs 67 RCT View evidence Registry trials NCT00941798 — Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma (COMPLETED) PHASE2 NCT01061333 — Early Airway Response to Allergen in Asthmatics (MK-0000-176) (COMPLETED) PHASE1 NCT00746330 — Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma (COMPLETED) PHASE2 NCT00711165 — Mometasone and Markers of Airway Inflammation (COMPLETED) PHASE4 NCT01555151 — Safety and Efficacy of Mometasone Furoate Delivered Via Concept1 Device or Twisthaler® Device in Adult and Adolescent Patients With Persistent Asthma (COMPLETED) PHASE2 NCT02415179 — Effect of Inhaled Mometasone/Formoterol Versus Inhaled Fluticasone/Salmeterol in Asthma Patients (COMPLETED) NA NCT00381485 — Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04431AM2)(COMPLETED) (COMPLETED) PHASE3 NCT06573164 — Allergic Rhinitis With/Without Asthma: Pre- and Post-Qipian Analysis (COMPLETED) Published literature Cochrane review Inhaled corticosteroids in children with persistent asthma: effects on growth (The Cochrane database of systematic reviews, 2014) Meta-analysis Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler(®) Device in Patients with Asthma (European journal of drug metabolism and pharmacokinetics, 2021) Meta-analysis Appraisal of lens opacity with mometasone furoate/formoterol fumarate combination in patients with COPD or asthma (Respiratory medicine, 2014) Meta-analysis Comparison of the efficacy and safety of mometasone furoate to other inhaled steroids for asthma: a meta-analysis (Asian Pacific journal of allergy and immunology, 2013) Meta-analysis Frequency of dosing and comparative doses of mometasone furoate: a meta-analysis (Respirology (Carlton, Vic.), 2009) Systematic review Measures to reduce maintenance therapy with oral corticosteroid in adults with severe asthma (Allergy and asthma proceedings, 2016) Clinical trial publication A Novel Metered Dose Inhaler Formulation of Triple-Drug Fixed-Dose Combination of Vilanterol, Glycopyrronium, and Fluticasone Furoate: A Phase III, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety in Indian Patients With Uncontrolled Asthma (Clinical therapeutics, 2025) Clinical trial publication Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial (The Lancet. Respiratory medicine, 2025) Clinical trial publication Efficacy and safety of novel fixed dose combination of vilanterol, glycopyrronium, and fluticasone furoate dry powder inhaler: A phase 3, randomized, non-inferiority trial compared with fixed dose combination of indacaterol, glycopyrronium, and mometasone furoate dry powder inhaler in Indian asthma patients (Respiratory medicine, 2025) Clinical trial publication Efficacy, Safety, and Systemic Exposure of Once-Daily Indacaterol Acetate in Pediatric Asthma: A Randomized, Double-Blind, Controlled Dose-Finding Study (Clinical drug investigation, 2023) Clinical trial publication Efficacy of mometasone/indacaterol/glycopyrronium in patients with inadequately controlled asthma with respect to baseline eosinophil count: Post hoc analysis of IRIDIUM study (Respiratory medicine, 2023) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
MONTELUKAST SODIUM	Small molecule	Approved	Strong	100	8 trials 2 Cochrane 2 Meta-analysis 28 Trial pubs 24 RCT View evidence Registry trials NCT02720081 — Study of MK-1029 in Participants With Persistent Asthma That Cannot Be Controlled With Montelukast (MK-1029-015) (COMPLETED) PHASE2 NCT00140881 — A Study to Determine the Effect of Montelukast Sodium as an Episode Modifier in the Treatment of Infrequent Episodic Asthma in Children (0476-165) (COMPLETED) PHASE4 NCT01659905 — Bioequivalency Study of Montelukast Chewable 5 mg Tablets Under Fasted Conditions (COMPLETED) EARLY_PHASE1 NCT00545324 — First Step With Singulair® Therapy (0476-323) (COMPLETED) PHASE4 NCT00442338 — Study of MK-0476 in Adult Patients With Acute Asthma (0476-334) (COMPLETED) PHASE3 NCT00504946 — Pharmacological Modulations of Allergen-Specific Immunotherapy (COMPLETED) PHASE3 NCT00319488 — Childhood Asthma Research and Education (CARE) Network Trial - Acute Intervention Management Strategies (AIMS) (COMPLETED) NA NCT00092092 — Study of Montelukast and Its Effect on Lower Leg Growth in Children With Asthma (MK-0476-254) (COMPLETED) PHASE4 Published literature Cochrane review Therapeutic effect of acupuncture combined montelukast sodium on cough variant asthma in children: A protocol for systematic review and meta-analysis (Medicine, 2021) Cochrane review Efficacy and safety of montelukast sodium combined with fluticasone in the treatment of adult bronchial asthma: A protocol for systematic review and meta-analysis (Medicine, 2020) Meta-analysis Clinical efficacy of montelukast sodium combination therapy for cough variant asthma in children: A meta-analysis (Pediatric pulmonology, 2024) Meta-analysis [Therapeutic effect and safety of montelukast sodium combined with budesonide in children with cough variant asthma: a Meta analysis] (Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2016) Clinical trial publication [Effect of modified painless wheat-grain blistering moxibustion on cough variant asthma of wind cold attacking the lung: a randomized controlled trial] (Zhongguo zhen jiu = Chinese acupuncture & moxibustion, 2026) Clinical trial publication Effect of budesonide combined with montelukast sodium on pulmonary function parameters and immunoglobulin levels in children with bronchial asthma (Allergologia et immunopathologia, 2023) Clinical trial publication Efficacy of montelukast sodium chewable tablets combined with inhaled budesonide in treating pediatric asthma and its effect on inflammatory factors (Die Pharmazie, 2019) Clinical trial publication [Clinical effect of fluticasone propionate, montelukast sodium and ketotifen in treatment of cough variant asthma in children] (Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2019) Clinical trial publication [Micro-invasive embedding combined with montelukast sodium for children cough variant asthma:a randomized controlled trial] (Zhongguo zhen jiu = Chinese acupuncture & moxibustion, 2017) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
PIRBUTEROL ACETATE	Small molecule	Approved	Strong	100	1 trials 3 Trial pubs 3 RCT View evidence Registry trials NCT00684827 — A Safety and Tolerability Study of Levalbuterol HFA Metered Dose Inhaler in Subjects With Asthma (COMPLETED) PHASE2 Published literature Clinical trial publication A device for overcoming discoordination with metered-dose inhalers (The Journal of allergy and clinical immunology, 1993) Clinical trial publication Comparative effects of pirbuterol acetate, metaproterenol, and placebo aerosols on pulmonary function and incidence of cardiac ectopy (The Journal of asthma : official journal of the Association for the Care of Asthma, 1989) Clinical trial publication Acute bronchial and cardiovascular effects of increasing doses of pirbuterol acetate aerosol in asthma (Annals of allergy, 1982) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
PREDNISOLONE SODIUM PHOSPHATE	Small molecule	Approved	Strong	100	8 trials 1 Trial pubs 1 RCT View evidence Registry trials NCT04874610 — Steroid Metabolism in Obese and Non-Obese Pediatric Patients Hospitalized for Status Asthmaticus (COMPLETED) NCT03133897 — Dexamethasone Versus Prednisone for Asthma Treatment in the Pediatric Inpatient Population; a Feasibility Study (TERMINATED) PHASE3 NCT06171932 — Comparison Of Efficacy Of Hydrocortisone And Methyl Prednisolone In Acute Severe Asthma (UNKNOWN) NCT01615874 — Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574) (WITHDRAWN) PHASE2 NCT01326494 — Reducing the Acute Care Burden of Childhood Asthma on Health Services in British Columbia (COMPLETED) PHASE4 NCT04276233 — Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma (COMPLETED) PHASE4 NCT05850143 — EFFECTIVENESS OF SINGLE DOSE ORAL DEXAMETHASONE VERSUS MULTIDOSE PREDNISOLONE FOR TREATMENT OF ACUTE EXACERBATIONS OF ASTHMA AMONG CHILDREN ATTENDING THE EMERGENCY DEPARTMENT OF CHILDREN HOSPITAL, ISLAMABAD (UNKNOWN) NA NCT00971893 — A Study To Assess The Safety And Effectiveness Of Medrol® In Acute Asthma In Indian Patients (WITHDRAWN) Published literature Clinical trial publication Prednisolone oral solution plus inhaled procaterol for acute asthma in children: a double-blind randomized controlled trial (Acta paediatrica Taiwanica = Taiwan er ke yi xue hui za zhi, 2007) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
PREDNISONE	Small molecule	Approved	Strong	100	8 trials 11 Cochrane 15 Meta-analysis 222 Trial pubs 163 RCT View evidence Registry trials NCT05035862 — Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma (TERMINATED) PHASE1 NCT06833814 — DOSE Trial: Optimal Dose of Oral Corticosteroids to Treat Asthma Exacerbations (NOT_YET_RECRUITING) PHASE4 NCT03133897 — Dexamethasone Versus Prednisone for Asthma Treatment in the Pediatric Inpatient Population; a Feasibility Study (TERMINATED) PHASE3 NCT00377364 — Acetaminophen (Tylenol) for Mood and Memory Changes Associated With Corticosteroid Therapy (COMPLETED) PHASE4 NCT03470311 — Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies (COMPLETED) PHASE3 NCT01615874 — Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574) (WITHDRAWN) PHASE2 NCT01621386 — Ventilatory Heterogeneity in Participants With Asthma (MK-0476-513) (COMPLETED) PHASE1 NCT01326494 — Reducing the Acute Care Burden of Childhood Asthma on Health Services in British Columbia (COMPLETED) PHASE4 Published literature Cochrane review The efficacy of dexamethasone compared to prednisone/prednisolone for the management of pediatric patients with acute exacerbation of asthma: a systematic review and meta-analysis (The Journal of asthma : official journal of the Association for the Care of Asthma, 2025) Cochrane review Dexamethasone versus prednisone/prednisolone in the management of pediatric patients with acute asthmatic exacerbations: a systematic review and meta-analysis (The Journal of asthma : official journal of the Association for the Care of Asthma, 2023) Cochrane review Safety of corticosteroids in young children with acute respiratory conditions: a systematic review and meta-analysis (BMJ open, 2019) Cochrane review Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for acute asthma (The Cochrane database of systematic reviews, 2018) Cochrane review Effects of prednisone on eosinophilic bronchitis in asthma: a systematic review and meta-analysis (Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia, 2014) Meta-analysis Dexamethasone Versus Prednisone or Prednisolone for Acute Pediatric Asthma Exacerbations in the Emergency Department: A Meta-Analysis (Pediatric emergency care, 2021) Meta-analysis Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma (The European respiratory journal, 2020) Clinical trial publication Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trial (The Lancet. Respiratory medicine, 2026) Clinical trial publication Modification of asthma treatment efficacy by healthcare access: A reanalysis of AsthmaNet Step-Up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations (STICS) clinical trial (Respiratory medicine, 2024) Clinical trial publication The Glucocorticoid Toxicity Index-Metabolic Domains, an abridged version of the Glucocorticoid Toxicity Index: post-hoc analysis of data from the ADVOCATE trial (The Lancet. Rheumatology, 2023) Clinical trial publication As-Needed Use of Short-Acting β(2)-Agonists Alone Versus As-Needed Use of Short-Acting β(2)-Agonists Plus Inhaled Corticosteroids in Pediatric Patients With Mild Intermittent (Step 1) Asthma: A Cost-Effectiveness Analysis (The journal of allergy and clinical immunology. In practice, 2022) Clinical trial publication Patient Advocates for Low-Income Adults with Moderate to Severe Asthma: A Randomized Clinical Trial (The journal of allergy and clinical immunology. In practice, 2020) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
SALMETEROL XINAFOATE	Small molecule	Approved	Strong	100	8 trials 2 Cochrane 4 Meta-analysis 44 Trial pubs 41 RCT View evidence Registry trials NCT02388373 — A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down (COMPLETED) PHASE4 NCT00529529 — Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma (COMPLETED) PHASE3 NCT00200967 — Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE) (COMPLETED) PHASE3 NCT05459194 — Efficacy and Safety Study of Fluticasone/Salmeterol Administered With Elpenhaler (COMPLETED) NA NCT00364442 — Repeat Dose Study of Fluticasone Propionate/Salmeterol Versus Fluticasone Propionate + Salmeterol In Asthmatics (COMPLETED) PHASE1 NCT02251379 — Environmental Control as Add-on Therapy in Childhood Asthma (COMPLETED) PHASE2 NCT00169546 — Study In Airway Physiology In Children SERETIDE DISKUS ® Inhlaer and FLIXOTIDE® Inhaler Are Trademarks of GSK Group of Companies. (COMPLETED) PHASE4 NCT00452348 — A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma (COMPLETED) PHASE4 Published literature Cochrane review Inhaled long acting beta agonists for stable chronic asthma (The Cochrane database of systematic reviews, 2003) Cochrane review Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma (The Cochrane database of systematic reviews, 2002) Meta-analysis COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada (Respiratory medicine, 2014) Meta-analysis Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma (Current medical research and opinion, 2007) Meta-analysis Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids (MedGenMed : Medscape general medicine, 2001) Systematic review Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol (Clinical therapeutics, 2009) Clinical trial publication Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study (The Lancet. Respiratory medicine, 2020) Clinical trial publication The efficacy and safety of fluticasone/salmeterol compared to fluticasone in children younger than four years of age (Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2019) Clinical trial publication Video education versus face-to-face education on inhaler technique for patients with well-controlled or partly-controlled asthma: A phase IV, open-label, non-inferiority, multicenter, randomized, controlled trial (PloS one, 2018) Clinical trial publication Pharmacokinetic analysis of inhaled salmeterol in asthma patients: Evidence from two dry powder inhalers (Biopharmaceutics & drug disposition, 2017) Clinical trial publication A Randomized Pragmatic Trial of Changing to and Stepping Down Fluticasone/Formoterol in Asthma (The journal of allergy and clinical immunology. In practice, 2017) Randomized controlled trial Clinical Bioequivalence of OT329 SOLIS and ADVAIR DISKUS in Adults with Asthma (Annals of the American Thoracic Society, 2017) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
TACROLIMUS ANHYDROUS	Small molecule	Approved	Strong	100	3 trials View evidence Registry trials NCT00189722 — Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma (COMPLETED) PHASE2 NCT00116103 — A Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent Asthma (COMPLETED) PHASE2 NCT00189787 — Dose Response of Inhaled Tacrolimus in Patients With Moderate Persistent Asthma (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
TIOTROPIUM BROMIDE	Small molecule	Approved	Strong	100	8 trials 3 Cochrane 1 Meta-analysis 7 Trial pubs 7 RCT View evidence Registry trials NCT06609941 — Additive Effects of Alternative Nostril Breathing with Pharmacological Management on Dyspnea and Control Pause in Patients with Bronchial Asthma (RECRUITING) NA NCT02682862 — Ultra-long Acting Bronchodilator Therapy in Smoking Asthmatics (COMPLETED) PHASE4 NCT01152450 — A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma (COMPLETED) PHASE2 NCT01316380 — Efficacy and Safety of 2 Doses of Tiotropium Via Respimat in Adult Patients With Mild Persistent Asthma (COMPLETED) PHASE3 NCT01634113 — Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma (COMPLETED) PHASE2 NCT02489981 — Specific Use-result Surveillance of Spiriva Respimat in Asthmatics (COMPLETED) NCT01172821 — Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II (COMPLETED) PHASE3 NCT00557700 — Study to Investigate the Effect of Inhaled Tiotropium Bromide on Neurokinin-A Induced Bronchoconstriction in Patients With Mild-to-moderate Asthma (COMPLETED) PHASE2 Published literature Cochrane review Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma (The Cochrane database of systematic reviews, 2016) Cochrane review Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma (The Cochrane database of systematic reviews, 2015) Cochrane review Anticholinergic agents for chronic asthma in adults (The Cochrane database of systematic reviews, 2004) Systematic review Tiotropium in the management of paediatric and adolescent asthma: Systematic review (Paediatric respiratory reviews, 2021) Systematic review Efficacy and safety of tiotropium in school-age children with moderate-to-severe symptomatic asthma: A systematic review (Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2017) Clinical trial publication Inhaled Glucocorticoid with or without Tiotropium Bromide for Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome (Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2019) Clinical trial publication Therapeutic Effects of a Long-Acting Cholinergic Receptor Blocker, Tiotropium Bromide, on Asthma (Medical science monitor : international medical journal of experimental and clinical research, 2018) Clinical trial publication Predictors of response to tiotropium versus salmeterol in asthmatic adults (The Journal of allergy and clinical immunology, 2013) Clinical trial publication Tiotropium bromide step-up therapy for adults with uncontrolled asthma (The New England journal of medicine, 2010) Clinical trial publication Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma (Chest, 2005) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
VILANTEROL TRIFENATATE	Small molecule	Approved	Strong	100	6 trials 4 Trial pubs 4 RCT View evidence Registry trials NCT01498653 — Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry (COMPLETED) PHASE3 NCT04265105 — Fluticasone-Vilanterol Once Daily Dose for the Treatment of Mild Asthma in Adults (COMPLETED) PHASE2, PHASE3 NCT03378648 — A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366 (COMPLETED) PHASE1, PHASE2 NCT06372496 — Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma (ACTIVE_NOT_RECRUITING) PHASE4 NCT03184987 — A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma (COMPLETED) PHASE3 NCT01498679 — Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry. (COMPLETED) PHASE3 Published literature Clinical trial publication Metabolomic changes related to airway inflammation, asthma pathogenesis and systemic activity following inhaled fluticasone furoate/vilanterol: a randomized controlled trial (Respiratory research, 2022) Clinical trial publication Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trial (Respiratory research, 2018) Clinical trial publication 24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids (The European respiratory journal, 2012) Clinical trial publication Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial (Thorax, 2012) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ZAFIRLUKAST	Small molecule	Approved	Strong	100	—	Open Targets, ChEMBL	ChEMBL Open Targets
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ADENOSINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ALFUZOSIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ALFUZOSIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMINOPHYLLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMIODARONE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMITRIPTYLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
APOMORPHINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
APRACLONIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
APRACLONIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ASENAPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ASPIRIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATENOLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATIPAMEZOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATROPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BENZPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BETHANIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BRIMONIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BRIMONIDINE TARTRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BROMOCRIPTINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CABERGOLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAFFEINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAFFEINE CITRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CARVEDILOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CARVEDILOL PHOSPHATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
CELIPROLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLORPROMAZINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CIPROFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLOMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLONIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOZAPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CYPROHEPTADINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DAPIPRAZOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DAPIPRAZOLE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DEBRISOQUIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DEFIBROTIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DEXMEDETOMIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DEXTROAMPHETAMINE SULFATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DIAZEPAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIPIVEFRIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DIPIVEFRIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DISULFIRAM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DOPAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DOXAZOSIN MESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DOXAZOSIN MESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DRONEDARONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DROXIDOPA Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
EPHEDRINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
EPHEDRINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
EPHEDRINE SULFATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
EPINEPHRINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
EPINEPHRINE BITARTRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
EPIRUBICIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ERGOLOID MESYLATES Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ERGOLOID MESYLATES, USP Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ERGOTAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ERGOTAMINE TARTRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ETHOXZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ETOMIDATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FENOLDOPAM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FLAVONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUMAZENIL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
GUANABENZ Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
GUANABENZ ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
GUANFACINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
GUANFACINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
HYDROXYAMPHETAMINE HYDROBROMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ILOPERIDONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
IMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ISOPROTERENOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ISOSORBIDE DINITRATE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ISTRADEFYLLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LABETALOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LABETALOL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
LEVODOPA Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LEVONORDEFRIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LISDEXAMFETAMINE DIMESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LOFEXIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LOFEXIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
LURASIDONE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MAFENIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MECAMYLAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MEFLOQUINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MEPERIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MEPHENTERMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MEPHENTERMINE SULFATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METARAMINOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METARAMINOL BITARTRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METHAMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METHAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHOTRIMEPRAZINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METHOXAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METHOXAMINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METHOXSALEN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHYLDOPA ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METHYLDOPATE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METOPROLOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METOPROLOL SUCCINATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MIANSERIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIDODRINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MIDODRINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
MILNACIPRAN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MIRTAZAPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MODAFINIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MOXISYLYTE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MOXONIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NAFTOPIDIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NALIDIXIC ACID Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NAPHAZOLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NAPHAZOLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NEFAZODONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NICARDIPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NICOTINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NIFEDIPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NOREPINEPHRINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NOREPINEPHRINE BITARTRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NORFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NORTRIPTYLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
OFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OLANZAPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
OXTRIPHYLLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
OXYMETAZOLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
OXYMETAZOLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PAPAVERINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PENTOXIFYLLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PERGOLIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENDIMETRAZINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENOXYBENZAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENOXYBENZAMINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENTOLAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENTOLAMINE MESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENYLEPHRINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENYLEPHRINE BITARTRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENYLEPHRINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENYLPROPANOLAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENYLPROPANOLAMINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENYLPROPANOLAMINE POLISTIREX Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENYTOIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PRAZOSIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PRAZOSIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PRAZOSIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PROMAZINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PROPIOMAZINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PSEUDOEPHEDRINE POLISTIREX Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
QUETIAPINE FUMARATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RACEPINEPHRINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RAUWOLFIA SERPENTINA Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
RAUWOLFIA SERPENTINA (USP) Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
REGADENOSON Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
REGADENOSON ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
REMIFENTANIL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RISPERIDONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SERTINDOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SILODOSIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SIROLIMUS Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
SODIUM CHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SULBACTAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TAMSULOSIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TAMSULOSIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TAZOBACTAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TERAZOSIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TERAZOSIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TETRAHYDROZOLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
THEOPHYLLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
THEOPHYLLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
THEOPHYLLINE SODIUM GLYCINATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
THIORIDAZINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TIZANIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TIZANIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TOLAZOLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TOLAZOLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TRAZODONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TRIFLUOPERAZINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TRIMIPRAMINE MALEATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TROGLITAZONE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
VIDARABINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
XYLAZINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
XYLOMETAZOLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
XYLOMETAZOLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
YOHIMBINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ZIPRASIDONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ASPIRIN	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
AZITHROMYCIN	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
CHOLECALCIFEROL	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
CLARITHROMYCIN	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
COLCHICINE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ERGOCALCIFEROL	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
LEBRIKIZUMAB	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
LEVOCETIRIZINE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
LORATADINE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
METHOTREXATE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
NEDOCROMIL	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
TELITHROMYCIN	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
UMECLIDINIUM	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ABLUKAST	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ACETAMINOPHEN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ATAPROST	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ATEZOLIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ATRELEUTON	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE DIPROPIONATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE SODIUM PHOSPHATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BIOTIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BROXATEROL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CARNITINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CHEMBL282468	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
DESLORATADINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DEXPRAMIPEXOLE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DOXOFYLLINE	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
DURVALUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FENOTEROL	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
FEVIPIPRANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FEXOFENADINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FISH OIL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FLUTICASONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FOROPAFANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FOSFRUCTOSE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FRENESLERBART	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GUSELKUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HUMAN IMMUNOGLOBULIN G	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IBUPROFEN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ICOSAPENT	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
INDACATEROL	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
INDACATEROL ACETATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INFLIXIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INSULIN HUMAN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IPRATROPIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ISRAPAFANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LANSOPRAZOLE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LENERCEPT	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LEVOCARNITINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MAGNESIUM SULFATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MASITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MEVONLERBART	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OCANKITUG	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PEMBROLIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PUMACTANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
QUINOTOLAST	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RABEPRAZOLE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RIVIPANSEL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RIVIPANSEL SODIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ROFLUMILAST	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
SETIPIPRANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SIMVASTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TIMAPIPRANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TIOTROPIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TISLELIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRALOKINUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRIAMCINOLONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRIAMCINOLONE HEXACETONIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
UMECLIDINIUM BROMIDE	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
VELIFLAPON	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VILANTEROL	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
ZINC SULFATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DARAPLADIB Repurposing	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
FENRETINIDE Repurposing	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
ALENDRONIC ACID	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
AMBRISENTAN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
AMELUBANT	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ANRUKINZUMAB	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ANTIPYRINE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ARGININE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
BENZOCAINE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
BOSENTAN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
BRODALUMAB	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
CLAZAKIZUMAB	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
DOCONEXENT	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ENOKIZUMAB	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
FIBOFLAPON	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
GALLOPAMIL	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
IMATINIB MESYLATE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
INDACATEROL MALEATE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ITRACONAZOLE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
MINOCYCLINE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
NADOLOL	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
OLODATEROL	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
OXELUMAB	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SECUKINUMAB	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SEMAGLUTIDE	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SIRUKUMAB	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SITAXENTAN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SODIUM NITRITE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
TERFENADINE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
TOFIMILAST	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
VIDUPIPRANT	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ABATACEPT	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ABEDITEROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ACLOPROXALAP	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ACREOZAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ADALIMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ADC3680	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ADERAMASTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AMLITELIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AMPHOTERICIN B	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANTI-PSGL-1 ANTIBODY SELK2	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANTIMONY	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ARFORMOTEROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ASM-024	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ASTEGOLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ATORVASTATIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ATULIFLAPON	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZD-5423	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZD-7624	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZD-8154	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZD-8848	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZD1981	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZD3199	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZX-100	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BAMAQUIMAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BAVITUXIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BEDORADRINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BEDORADRINE SULFATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BI-671800	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BIMOSIAMOSE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BREPOCITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BUTIXOCORT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CARMOTEROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CAVOSONSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CEP-1347	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHEMBL1082	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1922673	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL279597	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL3301673	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL361812	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL773	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL777	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CJM-112	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CLOPIDOGREL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CURCUMIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DACLIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DARBUFELONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DEFLAZACORT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DELGOCITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DEURUXOLITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DORNASE ALFA	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DOXYCYCLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DUVAKITUG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DUVELISIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ECULIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ELAREKIBEP	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENSIFENTRINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ESOMEPRAZOLE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ETANERCEPT	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ETOKIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FINGOLIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FLEZELASTINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FREVECITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GAMMA-TOCOPHEROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GEFAPIXANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GEMILUKAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GOLIMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GSK-2245035	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GSK-2269557	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GSK-256066	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GSK159802	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GW-274150	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GW-870086	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HT-0712	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IMATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IMITRODAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INCOMPLETE FREUND'S ADJUVANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INULIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IRALUKAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ISBUFYLLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ISOSPAGLUMIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ITEPEKIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
JNJ-39758979	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
JNJ-49095397	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
L-CITRULLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
L-NAME	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LAROPIPRANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LAZUCIRNON	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LENZILUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LEVOFLOXACIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LIGELIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LONDAMOCITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LUNSEKIMIG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MEDIUM-CHAIN TRIGLYCERIDES	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MELRILIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MEQUITAMIUM IODIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METFORMIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METHOXYVERAPAMIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MILVETEROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MK-1029	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
N6022	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NAFAGREL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NAVARIXIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NEMIRALISIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NOBERASTINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NOLPITANTIUM BESILATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OGLEMILAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ONTAZOLAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OXITRIPTAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OXYGEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PALIFERMIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PASCOLIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PBF-680	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEMIROLAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PF-00610355	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PF-03715455	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PF-4191834	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PICUMETEROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIOGLITAZONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIOGLITAZONE HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIRODOMAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PITRAKINRA	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PL-3994	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
POVORCITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PRASTERONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PROCATEROL HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PROPRANOLOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PUMAFENTRINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
QAV680	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
QAX-576	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
QUIFLAPON SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
QUILIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
QUISOVALIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
R-343	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
REMIBRUTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
REVAMILAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RILZABRUTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RISANKIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RITLECITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ROCATINLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ROSIGLITAZONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SENICAPOC	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SETILEUTON	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SILYMARIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SODIUM CHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SODIUM NITRATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SOLRIKITUG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SR-2640	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
STAPOKIBART	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SULUKAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TACROLIMUS	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TC-6987	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEPOXALIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TETRAZOLAST MEGLUMINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
THR-18	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIBENELAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TILREKIMIG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIPELUKAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TOREFORANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TOREFORANT TARTRATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TOZORAKIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TPI-1020	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRANIMILAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TREBANANIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TREGALIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRIGLYCERIDES, MEDIUM-CHAIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TROMETHAMINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VALATEGRAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VALATEGRAST HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VAPENDAVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VAROKIBART	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VELSECORAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VEREKITUG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZD-2138	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALPRENOLOL Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
AMIFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
BROLAMFETAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
CARZENIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIMECAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ELLAGIC ACID Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ENISOPROST Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FENCAMFAMIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FLEROXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
IDOXIFENE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
LYSERGIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
MERAFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
TENAMFETAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ZIDAPAMIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
GAMOLENIC ACID	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
ILOPROST	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
LOVASTATIN	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
LOXAPINE	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
MOGAMULIZUMAB	Biologic	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
VORICONAZOLE	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
ADRIFORANT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AM-211	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AMBROXOL ACEFYLLINATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ANAKINRA	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
APOCYNIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BITS-7201A	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CENDAKIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CHEMBL1009	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1200748	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL146	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL196	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL32	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL3989727	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL661	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
COMEKIBART	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CYSTEAMINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DESOXYRIBONUCLEASE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GINGER	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GINKGO	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GRC-6211	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GS 6201	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GSK-2239633	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GSK-679586A	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IMA-026	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ITOLIZUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LACTOBACILLUS ACIDOPHILUS	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LANINAMIVIR OCTANOATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LAS190792	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LINOLEIC ACID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MAGNESIUM STEARATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MEDI-4212	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MITOQUINOL CATION	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NAVAFENTEROL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PF-5212372	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PYRUVATE SODIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RESOLVIN E1	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RG-7152	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RG6341	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RG7185	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TAUROLITHOCHOLIC ACID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VEPALIMOMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VP-14637	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ZAVEGEPANT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
(R)-(+)-Zileuton	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ACLIDINIUM BROMIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ALBUTEROL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ASOBAMAST	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ATL-844	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BAMBUTEROL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BECLOMETHASONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BENRALIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BITOLTEROL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CHYMOTRYPSIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CINALUKAST	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CITALOPRAM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CLINPROST	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CROMOLYN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CV-6209	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEPEMOKIMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEXAMETHASONE PHOSPHORIC ACID	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DUPILUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
EFIPLADIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ENPROFYLLINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
EPHEDRINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
EPHEDRINE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ESCITALOPRAM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ETORICOXIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FENSPIRIDE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FLUPREDNISOLONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FLUTICASONE FUROATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FORMOTEROL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FPL-55712	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GEMCITABINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GLYCEROL, IODINATED	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GLYCOPYRRONIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GLYCOPYRRONIUM BROMIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GLYCOPYRRONIUM TOSYLATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
HYDROCORTISONE SODIUM SUCCINATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ICI-198615	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
IPRATROPIUM BROMIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ISOETHARINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ISOMAZOLE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
KHELLIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
KRYPTON KR 81M	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
L-648051	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LAS101057	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LEVALBUTEROL HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LEVOSALBUTAMOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LODOXAMIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LY-255283	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MANNITOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MEPOLIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METAPROTERENOL SULFATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METHACHOLINE CHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MIDAGLIZOLE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MOMETASONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MONTELUKAST	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NAVAFENTEROL SACCHARINATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
OMALIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
OXITROPIUM BROMIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PIMAGEDINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PIRBUTEROL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PIRMAGREL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PRANLUKAST	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PREDNISOLONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PROCATEROL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PROTOKYLOL HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
REPIRINAST	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RESLIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RIMITEROL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RO-201724	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SALMETEROL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SOY ISOFLAVONES	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SULFORAPHANE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SULOCHRIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SULOTROBAN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TALAROZOLE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TERBUTALINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TERBUTALINE SULFATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TEZEPELUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
THEOBROMINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
THEOPHYLLINE	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TOMELUKAST	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TRIAMCINOLONE ACETONIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ZILEUTON	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ALBUTEROL SULFATE	Small molecule	Approved	Strong	100	8 trials 18 Trial pubs 16 RCT View evidence Registry trials NCT02126839 — A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics (COMPLETED) PHASE3 NCT02479412 — A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma (COMPLETED) PHASE2 NCT00529529 — Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma (COMPLETED) PHASE3 NCT00667407 — Efficacy and Safety of Levalbuterol Versus Racemic Albuterol in Asthma (COMPLETED) PHASE3 NCT00200967 — Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE) (COMPLETED) PHASE3 NCT00096616 — Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma (COMPLETED) PHASE2 NCT01302587 — A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI) (COMPLETED) NCT02794519 — A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma (WITHDRAWN) PHASE2 Published literature Clinical trial publication Dose-Ranging and Cumulative Dose Studies of Albuterol Sulfate MDI in Co-Suspension Delivery™ Technology (AS MDI; PT007) in Patients with Asthma: the ASPEN and ANTORA Trials (Clinical drug investigation, 2021) Clinical trial publication Effect of heliox- and air-driven nebulized bronchodilator therapy on lung function in patients with asthma (Lung, 2014) Clinical trial publication Prospective, open-label assessment of albuterol sulfate hydrofluoroalkane metered-dose inhaler with new integrated dose counter (Allergy and asthma proceedings, 2013) Clinical trial publication The effect of heliox-driven bronchodilator aerosol therapy on pulmonary function tests in patients with asthma (The Journal of asthma : official journal of the Association for the Care of Asthma, 2002) Clinical trial publication Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial (JAMA, 2001) Randomized controlled trial Clinical comparability of ventolin formulated with hydrofluoroalkane or conventional chlorofluorocarbon propellants in children with asthma (Archives of pediatrics & adolescent medicine, 2000) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
AMINOPHYLLINE	Biologic	Approved	Strong	100	3 trials 11 Cochrane 7 Meta-analysis 156 Trial pubs 98 RCT View evidence Registry trials NCT00442338 — Study of MK-0476 in Adult Patients With Acute Asthma (0476-334) (COMPLETED) PHASE3 NCT03296579 — Non-invasive Ventilation vs. Standard Therapy for Children Hospitalized With an Acute Exacerbation of Asthma (UNKNOWN) NA NCT02270827 — A Pilot Study Into Health Pre and Post Treatment With Intravenous Aminophylline and Hydrocortisone in Severe Asthmatics (TERMINATED) Published literature Cochrane review Use of intravenous aminophylline in addition to the standard first-line treatment in children and adolescents with an acute asthma exacerbation: a systematic review and meta-analysis of randomised controlled trials (Archives of disease in childhood, 2025) Cochrane review Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews (The Cochrane database of systematic reviews, 2020) Cochrane review Guideline on management of the acute asthma attack in children by Italian Society of Pediatrics (Italian journal of pediatrics, 2018) Cochrane review Efficacy and side effects of intravenous theophylline in acute asthma: a systematic review and meta-analysis (Drug design, development and therapy, 2018) Cochrane review Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma (The Cochrane database of systematic reviews, 2012) Meta-analysis Intravenous Bronchodilators in Pediatric Critical Asthma: A Systematic Review and Network Meta-Analysis (Pediatric pulmonology, 2025) Meta-analysis Second-line treatment option for children aged 18 years and under with an acute severe asthma exacerbation: a systematic review and meta-analysis of randomised controlled trials (Archives of disease in childhood, 2025) Systematic review Use of ketamine in patients with refractory severe asthma exacerbations: systematic review of prospective studies (European journal of clinical pharmacology, 2022) Clinical trial publication Magnesium sulfate vs aminophylline as a second line of treatment in children with severe acute asthma. Randomized clinical trial (Andes pediatrica : revista Chilena de pediatria, 2021) Clinical trial publication Randomised comparison of intravenous magnesium sulphate, terbutaline and aminophylline for children with acute severe asthma (Acta paediatrica (Oslo, Norway : 1992), 2014) Clinical trial publication [Clinical efficacies of inhaled corticosteroids plus theophylline in the treatment of bronchial asthma] (Zhonghua yi xue za zhi, 2013) Clinical trial publication The efficacy and tolerability of intravenous montelukast in acute asthma exacerbations in Japanese patients (The Journal of asthma : official journal of the Association for the Care of Asthma, 2012) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
BECLOMETHASONE DIPROPIONATE	Small molecule	Approved	Strong	100	8 trials 18 Cochrane 21 Meta-analysis 541 Trial pubs 388 RCT View evidence Registry trials NCT04886999 — Study in Adult Patients With Moderate to Severe Asthma (COMPLETED) PHASE3 NCT01345916 — Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients (COMPLETED) PHASE3 NCT00200967 — Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE) (COMPLETED) PHASE3 NCT00094016 — Evaluation of Two Doses of QVAR by Breath Operated and Metered Dose Inhalers in Asthmatic Children (COMPLETED) PHASE3 NCT01520688 — Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth (COMPLETED) PHASE4 NCT01141439 — Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management (COMPLETED) NCT01287351 — Real-world Effectiveness and Cost-effectiveness of Qvar Versus FP, a US Study (COMPLETED) NCT00497237 — Clinical Trial of the Efficacy and Safety of Beclomethasone Dipropionate Plus Formoterol vs Fluticasone Propionate Plus Salmeterol in the 6 Months Step Down Treatment of Asthma (COMPLETED) PHASE3 Published literature Cochrane review Inhaled corticosteroids in children with persistent asthma: effects on growth (The Cochrane database of systematic reviews, 2014) Cochrane review Omalizumab for asthma in adults and children (The Cochrane database of systematic reviews, 2014) Cochrane review Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children (The Cochrane database of systematic reviews, 2010) Cochrane review Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children (The Cochrane database of systematic reviews, 2010) Cochrane review Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children (The Cochrane database of systematic reviews, 2007) Meta-analysis Adrenal suppression by inhaled corticosteroids in patients with asthma: A systematic review and quantitative analysis (Allergy and asthma proceedings, 2016) Systematic review Efficacy and safety of inhaled corticosteroids relative to fluticasone propionate: a systematic review of randomized controlled trials in asthma (Expert review of respiratory medicine, 2017) Systematic review Principal findings of systematic reviews for chronic treatment in childhood asthma (The Journal of asthma : official journal of the Association for the Care of Asthma, 2015) Clinical trial publication [Efficacy and safety of inhaled salbutamol sulfate combined with beclomethasone dipropionate in children with bronchial asthma: a randomized controlled study] (Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2025) Clinical trial publication Improved lung function with beclomethasone/formoterol versus beclomethasone alone in asthma: the FORCE2 study (The Journal of asthma : official journal of the Association for the Care of Asthma, 2026) Clinical trial publication Evaluating the impact of changing inhaler color on perception of symptoms and disease burden in patients with asthma: the FEEL study (The Journal of asthma : official journal of the Association for the Care of Asthma, 2025) Clinical trial publication Comparison of extrafine beclomethasone dipropionate/formoterol fumarate dry powder inhaler and pressurized metered-dose inhaler in Chinese patients with asthma: the FORTUNE study (The Journal of asthma : official journal of the Association for the Care of Asthma, 2024) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
BETAMETHASONE ACETATE	Small molecule	Approved	Strong	100	No indexed hits View evidence CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
BUDESONIDE	Small molecule	Approved	Strong	100	8 trials 57 Cochrane 66 Meta-analysis 910 Trial pubs 793 RCT View evidence Registry trials NCT04609904 — Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS) (COMPLETED) PHASE3 NCT00235911 — Symbicort Single Inhaler Therapy for Asthma in a General Practice Setting (COMPLETED) PHASE3 NCT03788057 — Inflammatory Indices in Predicting the Failure of Inhaled Corticosteroids Reduction in Young Participants With Asthma (COMPLETED) NA NCT01520688 — Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth (COMPLETED) PHASE4 NCT01444430 — A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents (COMPLETED) PHASE3 NCT06080945 — Tailored Pharmacist-led Intervention to Improve Adherence to Budesonide (UNKNOWN) NA NCT00641446 — Varicella Vaccination With Pulmicort (COMPLETED) PHASE4 NCT03319043 — Observation of Cough Variant Asthma Treated in Combination of Chanqin Granules. (UNKNOWN) PHASE1, PHASE2 Published literature Cochrane review Adverse events of inhaled corticosteroids in adult patients with asthma or chronic obstructive pulmonary disease: pairwise, network and dose-response meta-analyses (BMJ evidence-based medicine, 2026) Cochrane review Efficacy and safety profile of doxofylline in asthma: a meta-analysis (The Journal of asthma : official journal of the Association for the Care of Asthma, 2025) Cochrane review Single maintenance and reliever therapy in treatment of asthma exacerbations (Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2022) Cochrane review A review of the efficacy and safety of fluticasone propionate/formoterol fixed-dose combination (Expert review of respiratory medicine, 2022) Cochrane review Combination fixed-dose β agonist and steroid inhaler as required for adults or children with mild asthma: a Cochrane systematic review (BMJ evidence-based medicine, 2022) Meta-analysis Effect of aerosol inhalation of budesonide on respiratory symptoms and inflammatory factors in patients with asthma: a meta-analysis (The Journal of asthma : official journal of the Association for the Care of Asthma, 2024) Meta-analysis Clinical efficacy of montelukast sodium combination therapy for cough variant asthma in children: A meta-analysis (Pediatric pulmonology, 2024) Meta-analysis Effect of Montelukast Combined with Budesonide on Inflammatory Response and Pulmonary Function in Children with Cough Variant Asthma: A Meta-analysis (Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2023) Systematic review [IS AS NEEDED THERAPY WITH AN INHALED BUDESONIDE/FORMOTEROL COMBINATION ONLY WHEN SYMPTOMATIC AS AN OPTION IN THE MANAGEMENT OF PATIENTS WITH MILD ASTHMA?] (Arerugi = [Allergy], 2025) Systematic review Quantitative comparison of different inhaled corticosteroids in the treatment of asthma in children (Pediatric research, 2023) Clinical trial publication Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials (The Lancet. Respiratory medicine, 2026) Clinical trial publication Analysis of risk factors for recurrence in children with asthmatic bronchopneumonia during remission and discussion on the therapeutic effect of diprophylline combined with budesonide (Pakistan journal of pharmaceutical sciences, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
CICLESONIDE	Small molecule	Approved	Strong	100	8 trials 9 Cochrane 10 Meta-analysis 77 Trial pubs 74 RCT View evidence Registry trials NCT00163371 — Effects of Inhaled Ciclesonide Versus Fluticasone Propionate Versus Placebo on Lower Leg Growth in Prepubertal Children With Mild Persistent Asthma (6 to 12 y) (BY9010/M1-208) (COMPLETED) PHASE3 NCT01455194 — Effect of High Dose Ciclesonide on Asthma Control (COMPLETED) PHASE3 NCT00163397 — Efficacy of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 y) (BY9010/M1-137) (COMPLETED) PHASE3 NCT06272370 — Individualizing Treatment for Asthma in Primary Care (COMPLETED) PHASE4 NCT03839433 — The Mannitol-Asthma-Ciclesonide-Study (COMPLETED) PHASE4 NCT00174733 — Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid (COMPLETED) PHASE3 NCT00525772 — Effect of Ciclesonide on Exercise Induced Bronchoconstriction (COMPLETED) PHASE3 NCT00163293 — Efficacy of Ciclesonide Inhaled Once Daily Versus Other Corticosteroids Used for Treatment of Mild Asthma in Children (4 to 11 Years) (BY9010/CA-101) (COMPLETED) PHASE3 Published literature Cochrane review Adverse events of inhaled corticosteroids in adult patients with asthma or chronic obstructive pulmonary disease: pairwise, network and dose-response meta-analyses (BMJ evidence-based medicine, 2026) Cochrane review Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids (The Cochrane database of systematic reviews, 2015) Cochrane review Inhaled corticosteroids in children with persistent asthma: dose-response effects on growth (The Cochrane database of systematic reviews, 2014) Cochrane review Inhaled corticosteroids in children with persistent asthma: effects on growth (The Cochrane database of systematic reviews, 2014) Cochrane review Ciclesonide: long-term treatment of persistent asthma--no clear progress (Prescrire international, 2013) Meta-analysis Inhaled ciclesonide for outpatients with COVID-19: A meta-analysis (Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2022) Meta-analysis Extrafine Versus Fine Inhaled Corticosteroids in Relation to Asthma Control: A Systematic Review and Meta-Analysis of Observational Real-Life Studies (The journal of allergy and clinical immunology. In practice, 2018) Meta-analysis Adrenal suppression by inhaled corticosteroids in patients with asthma: A systematic review and quantitative analysis (Allergy and asthma proceedings, 2016) Systematic review Local and systemic adverse effects of inhaled corticosteroids - Does ciclesonide differ from other inhaled corticosteroids? (Respiratory medicine, 2025) Systematic review Quantitative comparison of different inhaled corticosteroids in the treatment of asthma in children (Pediatric research, 2023) Systematic review Efficacy and safety of inhaled corticosteroids relative to fluticasone propionate: a systematic review of randomized controlled trials in asthma (Expert review of respiratory medicine, 2017) Clinical trial publication Inhaled ciclesonide does not affect production of antibodies or elimination of virus in patients with COVID-19: Subanalysis of a multicenter, open-label randomized trial (Drug discoveries & therapeutics, 2023) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
CORTISONE ACETATE	Small molecule	Approved	Strong	100	—	Open Targets, ChEMBL	ChEMBL Open Targets
CROMOLYN SODIUM	Small molecule	Approved	Strong	100	3 trials 1 Cochrane 111 Trial pubs 61 RCT View evidence Registry trials NCT01346852 — Predictive Ability of Therapeutic Risk Factors in Pediatric and Adult Asthma Patients (COMPLETED) NCT00943397 — Extended Safety Study of Montelukast in Infants and Young Children With Chronic Asthma (0476-232) (COMPLETED) PHASE3 NCT06535087 — The Impact of Airway Allergic Diseases on Children's and Parents' Quality of Life (RECRUITING) Published literature Cochrane review Asthma controller therapy during pregnancy (American journal of obstetrics and gynecology, 2005) Systematic review Nebulized Inhaled Corticosteroids in Asthma Treatment in Children 5 Years or Younger: A Systematic Review and Global Expert Analysis (The journal of allergy and clinical immunology. In practice, 2020) Clinical trial publication Salivary cortisol monitoring: determination of reference values in healthy children and application in asthmatic children (Allergy and asthma proceedings, 2012) Clinical trial publication [Effects of acupuncture on the pulmonary function and heart rate variability in different state of bronchial asthma] (Zhen ci yan jiu = Acupuncture research, 2007) Clinical trial publication [Lung functioning changes of asthmatic adults in treatment with cromolyn sodium and beclomethasone] (Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993), 2004) Clinical trial publication Evaluation of parental preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: a randomized, open-label, crossover study (The Journal of asthma : official journal of the Association for the Care of Asthma, 2003) Clinical trial publication Effects of budesonide inhalation suspension compared with cromolyn sodium nebulizer solution on health status and caregiver quality of life in childhood asthma (Pediatrics, 2003) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
DEXAMETHASONE	Small molecule	Approved	Strong	100	8 trials 7 Cochrane 11 Meta-analysis 60 Trial pubs 39 RCT View evidence Registry trials NCT03133897 — Dexamethasone Versus Prednisone for Asthma Treatment in the Pediatric Inpatient Population; a Feasibility Study (TERMINATED) PHASE3 NCT01326494 — Reducing the Acute Care Burden of Childhood Asthma on Health Services in British Columbia (COMPLETED) PHASE4 NCT05850143 — EFFECTIVENESS OF SINGLE DOSE ORAL DEXAMETHASONE VERSUS MULTIDOSE PREDNISOLONE FOR TREATMENT OF ACUTE EXACERBATIONS OF ASTHMA AMONG CHILDREN ATTENDING THE EMERGENCY DEPARTMENT OF CHILDREN HOSPITAL, ISLAMABAD (UNKNOWN) NA NCT07228052 — Giving Asthmatics Intramuscular Steroids for Preventing Return to the Emergency Department (NOT_YET_RECRUITING) PHASE4 NCT00942201 — Comparison of Oral Dexamethasone Doses in Asthma Exacerbation (COMPLETED) NA NCT02725008 — Trial of One Versus Two Doses of Dexamethasone for Pediatric Asthma Exacerbation (COMPLETED) PHASE3 NCT04278404 — Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (RECRUITING) NCT03900624 — Ideal Steroids for Asthma Treatment in the PICU (COMPLETED) PHASE4 Published literature Cochrane review The efficacy of dexamethasone compared to prednisone/prednisolone for the management of pediatric patients with acute exacerbation of asthma: a systematic review and meta-analysis (The Journal of asthma : official journal of the Association for the Care of Asthma, 2025) Cochrane review Dexamethasone versus prednisone/prednisolone in the management of pediatric patients with acute asthmatic exacerbations: a systematic review and meta-analysis (The Journal of asthma : official journal of the Association for the Care of Asthma, 2023) Cochrane review Safety of corticosteroids in young children with acute respiratory conditions: a systematic review and meta-analysis (BMJ open, 2019) Cochrane review Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for acute asthma (The Cochrane database of systematic reviews, 2018) Cochrane review Different oral corticosteroid regimens for acute asthma (The Cochrane database of systematic reviews, 2016) Meta-analysis Oral systemic corticosteroids in children with acute asthma exacerbations: a systematic review and network meta-analysis (Archives of disease in childhood, 2025) Meta-analysis Dexamethasone Versus Prednisone or Prednisolone for Acute Pediatric Asthma Exacerbations in the Emergency Department: A Meta-Analysis (Pediatric emergency care, 2021) Clinical trial publication Circulating miRNAs and childhood asthma ICS response: a stratified analysis in the intervention arm of an RCT with vitamin D effect modification (Thorax, 2025) Clinical trial publication Dexamethasone versus methylprednisolone for critical asthma: A single center, open-label, parallel-group clinical trial (Pediatric pulmonology, 2023) Clinical trial publication Single-Dose Dexamethasone Is Not Inferior to 2 Doses in Mild to Moderate Pediatric Asthma Exacerbations in the Emergency Department (Pediatric emergency care, 2022) Clinical trial publication A Randomized Controlled Study Addressing Dexamethasone Tolerability in the Treatment of Acute Asthma in Children: Mary Poppins on Trial! (Journal of pharmacy practice, 2023) Clinical trial publication Dexamethasone-Induced FKBP51 Expression in CD4(+) T-Lymphocytes Is Uniquely Associated With Worse Asthma Control in Obese Children With Asthma (Frontiers in immunology, 2021) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
DEXAMETHASONE SODIUM PHOSPHATE	Small molecule	Approved	Strong	100	8 trials View evidence Registry trials NCT03133897 — Dexamethasone Versus Prednisone for Asthma Treatment in the Pediatric Inpatient Population; a Feasibility Study (TERMINATED) PHASE3 NCT01326494 — Reducing the Acute Care Burden of Childhood Asthma on Health Services in British Columbia (COMPLETED) PHASE4 NCT05850143 — EFFECTIVENESS OF SINGLE DOSE ORAL DEXAMETHASONE VERSUS MULTIDOSE PREDNISOLONE FOR TREATMENT OF ACUTE EXACERBATIONS OF ASTHMA AMONG CHILDREN ATTENDING THE EMERGENCY DEPARTMENT OF CHILDREN HOSPITAL, ISLAMABAD (UNKNOWN) NA NCT07228052 — Giving Asthmatics Intramuscular Steroids for Preventing Return to the Emergency Department (NOT_YET_RECRUITING) PHASE4 NCT00942201 — Comparison of Oral Dexamethasone Doses in Asthma Exacerbation (COMPLETED) NA NCT02725008 — Trial of One Versus Two Doses of Dexamethasone for Pediatric Asthma Exacerbation (COMPLETED) PHASE3 NCT04278404 — Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (RECRUITING) NCT03900624 — Ideal Steroids for Asthma Treatment in the PICU (COMPLETED) PHASE4 CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
EPHEDRINE SULFATE	Small molecule	Approved	Strong	100	4 Trial pubs 1 RCT View evidence Published literature Clinical trial publication A comparative study of bronchodilator effects of carbuterol and ephedrine (JAMA, 1979) Clinical trial publication Double-blind trial of oral carbuterol in bronchial asthma (Annals of allergy, 1977) Clinical trial publication Ephedrine therapy in asthmatic children. Clinical tolerance and absence of side effects (JAMA, 1977) Clinical trial publication Subsensitivity to epinephrine following the administration of epinephrine and ephedrine to normal individuals (The Journal of allergy and clinical immunology, 1975) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
EPINEPHRINE	Small molecule	Approved	Strong	100	—	Open Targets, ChEMBL	ChEMBL Open Targets
FLUNISOLIDE	Small molecule	Approved	Strong	100	3 trials 4 Cochrane 6 Meta-analysis 53 Trial pubs 41 RCT View evidence Registry trials NCT02404103 — Flunisolide HFA in Children With Small Airway Disease (COMPLETED) NA NCT00203684 — Mentored Patient-Oriented Research Career Development Award (COMPLETED) PHASE1 NCT01347060 — Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy (COMPLETED) Published literature Cochrane review Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations (Journal of aerosol medicine and pulmonary drug delivery, 2016) Cochrane review Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids (The Cochrane database of systematic reviews, 2015) Cochrane review Inhaled corticosteroids in children with persistent asthma: effects on growth (The Cochrane database of systematic reviews, 2014) Cochrane review Effectiveness of inhaled corticosteroids in the treatment of acute asthma in children in the emergency department: a meta-analysis (Annals of medicine, 2014) Meta-analysis Relative oral corticosteroid-sparing effect of 7 inhaled corticosteroids in chronic asthma: a meta-analysis (Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2008) Meta-analysis Meta-analysis finds use of inhaled corticosteroids during pregnancy safe: a systematic meta-analysis review (Human & experimental toxicology, 2006) Meta-analysis Improved asthma control after changing from low-to-medium doses of other inhaled corticosteroids to low-dose fluticasone propionate (MedGenMed : Medscape general medicine, 2001) Systematic review Inhaled versus systemic corticosteroids for acute asthma in children. A systematic review (Pediatric pulmonology, 2014) Clinical trial publication Linear growth and bone maturation are unaffected by 1 year of therapy with inhaled flunisolide hydrofluoroalkane in prepubescent children with mild persistent asthma: a randomized, double-blind, placebo-controlled trial (Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2011) Clinical trial publication High-dose inhaled flunisolide versus budesonide in the treatment of acute asthma exacerbations in preschool-age children (International journal of immunopathology and pharmacology, 2009) Clinical trial publication Flunisolide decreases exhaled nitric oxide and nitrotyrosine levels in asthmatic children (Mediators of inflammation, 2006) Clinical trial publication Effects of long-term inhaled corticosteroids on adrenal function in patients with asthma (Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2006) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
FLUTICASONE PROPIONATE	Small molecule	Approved	Strong	100	8 trials 22 Cochrane 40 Meta-analysis 572 Trial pubs 501 RCT View evidence Registry trials NCT02388373 — A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down (COMPLETED) PHASE4 NCT01669070 — A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI) (COMPLETED) PHASE1 NCT01165138 — Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics (COMPLETED) PHASE3 NCT00163371 — Effects of Inhaled Ciclesonide Versus Fluticasone Propionate Versus Placebo on Lower Leg Growth in Prepubertal Children With Mild Persistent Asthma (6 to 12 y) (BY9010/M1-208) (COMPLETED) PHASE3 NCT01520688 — Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth (COMPLETED) PHASE4 NCT00400855 — Study on the Effects of an AMP Challenge on Asthmatic Patients Following Treatment With Fluticasone Propionate (COMPLETED) PHASE2 NCT01141439 — Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management (COMPLETED) NCT01516073 — 12-Week Study in Adult Subjects With Asthma (COMPLETED) PHASE2 Published literature Cochrane review A review of the efficacy and safety of fluticasone propionate/formoterol fixed-dose combination (Expert review of respiratory medicine, 2022) Cochrane review The efficacy and safety of fluticasone propionate/formoterol compared with fluticasone propionate/salmeterol in treating pediatric asthma: a systematic review and meta-analysis (The Journal of international medical research, 2020) Cochrane review Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations (Journal of aerosol medicine and pulmonary drug delivery, 2016) Cochrane review Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids (The Cochrane database of systematic reviews, 2015) Cochrane review Inhaled corticosteroids in children with persistent asthma: effects on growth (The Cochrane database of systematic reviews, 2014) Meta-analysis Clinical efficacy of montelukast sodium combination therapy for cough variant asthma in children: A meta-analysis (Pediatric pulmonology, 2024) Meta-analysis An efficacy and safety evaluation of montelukast + fluticasone propionate vs. fluticasone propionate in the treatment of cough variant asthma in children: a meta-analysis (BMC pulmonary medicine, 2023) Meta-analysis Efficacy and safety of fluticasone propionate/salmeterol and fluticasone propionate monotherapy in step-up treatment of childhood asthma: A systematic review and meta-analysis (Heart & lung : the journal of critical care, 2024) Meta-analysis Impact of inhaled fluticasone propionate/salmeterol on health-related quality of life in asthma: A network meta-analysis (Respiratory medicine, 2022) Meta-analysis Quantitative comparison of dose-effect and time-course of fluticasone furoate and fluticasone propionate in adult and adolescent patients with persistent asthma: A systematic review and meta-analysis (Respirology (Carlton, Vic.), 2022) Systematic review Local and systemic adverse effects of inhaled corticosteroids - Does ciclesonide differ from other inhaled corticosteroids? (Respiratory medicine, 2025) Systematic review Exploring the Relationship between Inhaled Corticosteroid Usage, Asthma Severity, and Sleep-Disordered Breathing: A Systematic Literature Review (Advances in respiratory medicine, 2024) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
FORMOTEROL FUMARATE	Small molecule	Approved	Strong	100	8 trials 6 Cochrane 7 Meta-analysis 58 Trial pubs 53 RCT View evidence Registry trials NCT02388373 — A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down (COMPLETED) PHASE4 NCT04886999 — Study in Adult Patients With Moderate to Severe Asthma (COMPLETED) PHASE3 NCT04609904 — Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS) (COMPLETED) PHASE3 NCT00235911 — Symbicort Single Inhaler Therapy for Asthma in a General Practice Setting (COMPLETED) PHASE3 NCT00746330 — Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma (COMPLETED) PHASE2 NCT01444430 — A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents (COMPLETED) PHASE3 NCT01711086 — Safety and Efficacy of the Inspiromatic Inhaler in Comparison to the Aerolizer Inhaler When Delivering Formoterol (UNKNOWN) PHASE1, PHASE2 NCT03319043 — Observation of Cough Variant Asthma Treated in Combination of Chanqin Granules. (UNKNOWN) PHASE1, PHASE2 Published literature Cochrane review A review of the efficacy and safety of fluticasone propionate/formoterol fixed-dose combination (Expert review of respiratory medicine, 2022) Cochrane review Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations (Journal of aerosol medicine and pulmonary drug delivery, 2016) Cochrane review Formoterol for acute asthma in the emergency department: a systematic review with meta-analysis (Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2010) Cochrane review Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid (The Cochrane database of systematic reviews, 2007) Cochrane review Inhaled long acting beta agonists for stable chronic asthma (The Cochrane database of systematic reviews, 2003) Meta-analysis Appraisal of lens opacity with mometasone furoate/formoterol fumarate combination in patients with COPD or asthma (Respiratory medicine, 2014) Meta-analysis Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years (Health technology assessment (Winchester, England), 2008) Meta-analysis Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over (Health technology assessment (Winchester, England), 2008) Systematic review Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol (Clinical therapeutics, 2009) Clinical trial publication Safety and tolerability of the low global warming potential propellant HFA-152a in patients with asthma receiving beclometasone dipropionate/formoterol fumarate/glycopyrronium: The TRECOS study (Respiratory medicine, 2026) Clinical trial publication Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials (The Lancet. Respiratory medicine, 2026) Clinical trial publication Improved lung function with beclomethasone/formoterol versus beclomethasone alone in asthma: the FORCE2 study (The Journal of asthma : official journal of the Association for the Care of Asthma, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
HYDROCORTISONE	Small molecule	Approved	Strong	100	—	Open Targets, ChEMBL	ChEMBL Open Targets
MENTHOL	Small molecule	Approved	Strong	100	1 trials 2 Trial pubs 2 RCT View evidence Registry trials NCT07500974 — Efficacy of L-menthol on Breathlessness in Asthma (NOT_YET_RECRUITING) PHASE2 Published literature Clinical trial publication Effect of menthol vapour on airway hyperresponsiveness in patients with mild asthma (Respiratory medicine, 1995) Clinical trial publication Comparative taste evaluation of aerosolized formulations of triamcinolone acetonide, flunisolide, and flunisolide with menthol (Clinical therapeutics, 1993) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
METHYLPREDNISOLONE	Small molecule	Approved	Strong	100	—	Open Targets, ChEMBL	ChEMBL Open Targets
METHYLPREDNISOLONE ACETATE	Small molecule	Approved	Strong	100	8 trials 2 Trial pubs 1 RCT View evidence Registry trials NCT04874610 — Steroid Metabolism in Obese and Non-Obese Pediatric Patients Hospitalized for Status Asthmaticus (COMPLETED) NCT06171932 — Comparison Of Efficacy Of Hydrocortisone And Methyl Prednisolone In Acute Severe Asthma (UNKNOWN) NCT00971893 — A Study To Assess The Safety And Effectiveness Of Medrol® In Acute Asthma In Indian Patients (WITHDRAWN) NCT03900624 — Ideal Steroids for Asthma Treatment in the PICU (COMPLETED) PHASE4 NCT07455396 — Pediatric Asthma Trial of Corticosteroid Heterogeneity (PATCH): Trial of Dexamethasone Versus Methylprednisolone for Pediatric Critical Asthma (NOT_YET_RECRUITING) PHASE2 NCT02872597 — Phase I, Placebo-Controlled, Blinded Pilot Study of Ipratropium in Children Admitted to the ICU With Status Asthmaticus (COMPLETED) PHASE1 NCT00576069 — Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma (RECRUITING) NCT00627731 — Oral Glucocorticosteroid in the Treatment of Severe Asthma Exacerbation in Hospitalized Patients (COMPLETED) PHASE4 Published literature Clinical trial publication Intramuscular methylprednisolone acetate for the prevention of relapse in acute asthma (Annals of emergency medicine, 1993) Clinical trial publication Comparison of preseasonal and coseasonal Allpyral with Depo-Medrone in summer hay-fever (British medical journal, 1969) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
METHYLPREDNISOLONE SODIUM SUCCINATE	Small molecule	Approved	Strong	100	—	Open Targets, ChEMBL	ChEMBL Open Targets
MOMETASONE FUROATE	Small molecule	Approved	Strong	100	8 trials 1 Cochrane 5 Meta-analysis 73 Trial pubs 67 RCT View evidence Registry trials NCT00941798 — Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma (COMPLETED) PHASE2 NCT01061333 — Early Airway Response to Allergen in Asthmatics (MK-0000-176) (COMPLETED) PHASE1 NCT00746330 — Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma (COMPLETED) PHASE2 NCT00711165 — Mometasone and Markers of Airway Inflammation (COMPLETED) PHASE4 NCT01555151 — Safety and Efficacy of Mometasone Furoate Delivered Via Concept1 Device or Twisthaler® Device in Adult and Adolescent Patients With Persistent Asthma (COMPLETED) PHASE2 NCT02415179 — Effect of Inhaled Mometasone/Formoterol Versus Inhaled Fluticasone/Salmeterol in Asthma Patients (COMPLETED) NA NCT00381485 — Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04431AM2)(COMPLETED) (COMPLETED) PHASE3 NCT06573164 — Allergic Rhinitis With/Without Asthma: Pre- and Post-Qipian Analysis (COMPLETED) Published literature Cochrane review Inhaled corticosteroids in children with persistent asthma: effects on growth (The Cochrane database of systematic reviews, 2014) Meta-analysis Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler(®) Device in Patients with Asthma (European journal of drug metabolism and pharmacokinetics, 2021) Meta-analysis Appraisal of lens opacity with mometasone furoate/formoterol fumarate combination in patients with COPD or asthma (Respiratory medicine, 2014) Meta-analysis Comparison of the efficacy and safety of mometasone furoate to other inhaled steroids for asthma: a meta-analysis (Asian Pacific journal of allergy and immunology, 2013) Meta-analysis Frequency of dosing and comparative doses of mometasone furoate: a meta-analysis (Respirology (Carlton, Vic.), 2009) Systematic review Measures to reduce maintenance therapy with oral corticosteroid in adults with severe asthma (Allergy and asthma proceedings, 2016) Clinical trial publication A Novel Metered Dose Inhaler Formulation of Triple-Drug Fixed-Dose Combination of Vilanterol, Glycopyrronium, and Fluticasone Furoate: A Phase III, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety in Indian Patients With Uncontrolled Asthma (Clinical therapeutics, 2025) Clinical trial publication Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial (The Lancet. Respiratory medicine, 2025) Clinical trial publication Efficacy and safety of novel fixed dose combination of vilanterol, glycopyrronium, and fluticasone furoate dry powder inhaler: A phase 3, randomized, non-inferiority trial compared with fixed dose combination of indacaterol, glycopyrronium, and mometasone furoate dry powder inhaler in Indian asthma patients (Respiratory medicine, 2025) Clinical trial publication Efficacy, Safety, and Systemic Exposure of Once-Daily Indacaterol Acetate in Pediatric Asthma: A Randomized, Double-Blind, Controlled Dose-Finding Study (Clinical drug investigation, 2023) Clinical trial publication Efficacy of mometasone/indacaterol/glycopyrronium in patients with inadequately controlled asthma with respect to baseline eosinophil count: Post hoc analysis of IRIDIUM study (Respiratory medicine, 2023) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
MONTELUKAST SODIUM	Small molecule	Approved	Strong	100	8 trials 2 Cochrane 2 Meta-analysis 28 Trial pubs 24 RCT View evidence Registry trials NCT02720081 — Study of MK-1029 in Participants With Persistent Asthma That Cannot Be Controlled With Montelukast (MK-1029-015) (COMPLETED) PHASE2 NCT00140881 — A Study to Determine the Effect of Montelukast Sodium as an Episode Modifier in the Treatment of Infrequent Episodic Asthma in Children (0476-165) (COMPLETED) PHASE4 NCT01659905 — Bioequivalency Study of Montelukast Chewable 5 mg Tablets Under Fasted Conditions (COMPLETED) EARLY_PHASE1 NCT00545324 — First Step With Singulair® Therapy (0476-323) (COMPLETED) PHASE4 NCT00442338 — Study of MK-0476 in Adult Patients With Acute Asthma (0476-334) (COMPLETED) PHASE3 NCT00504946 — Pharmacological Modulations of Allergen-Specific Immunotherapy (COMPLETED) PHASE3 NCT00319488 — Childhood Asthma Research and Education (CARE) Network Trial - Acute Intervention Management Strategies (AIMS) (COMPLETED) NA NCT00092092 — Study of Montelukast and Its Effect on Lower Leg Growth in Children With Asthma (MK-0476-254) (COMPLETED) PHASE4 Published literature Cochrane review Therapeutic effect of acupuncture combined montelukast sodium on cough variant asthma in children: A protocol for systematic review and meta-analysis (Medicine, 2021) Cochrane review Efficacy and safety of montelukast sodium combined with fluticasone in the treatment of adult bronchial asthma: A protocol for systematic review and meta-analysis (Medicine, 2020) Meta-analysis Clinical efficacy of montelukast sodium combination therapy for cough variant asthma in children: A meta-analysis (Pediatric pulmonology, 2024) Meta-analysis [Therapeutic effect and safety of montelukast sodium combined with budesonide in children with cough variant asthma: a Meta analysis] (Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2016) Clinical trial publication [Effect of modified painless wheat-grain blistering moxibustion on cough variant asthma of wind cold attacking the lung: a randomized controlled trial] (Zhongguo zhen jiu = Chinese acupuncture & moxibustion, 2026) Clinical trial publication Effect of budesonide combined with montelukast sodium on pulmonary function parameters and immunoglobulin levels in children with bronchial asthma (Allergologia et immunopathologia, 2023) Clinical trial publication Efficacy of montelukast sodium chewable tablets combined with inhaled budesonide in treating pediatric asthma and its effect on inflammatory factors (Die Pharmazie, 2019) Clinical trial publication [Clinical effect of fluticasone propionate, montelukast sodium and ketotifen in treatment of cough variant asthma in children] (Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2019) Clinical trial publication [Micro-invasive embedding combined with montelukast sodium for children cough variant asthma:a randomized controlled trial] (Zhongguo zhen jiu = Chinese acupuncture & moxibustion, 2017) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
PIRBUTEROL ACETATE	Small molecule	Approved	Strong	100	1 trials 3 Trial pubs 3 RCT View evidence Registry trials NCT00684827 — A Safety and Tolerability Study of Levalbuterol HFA Metered Dose Inhaler in Subjects With Asthma (COMPLETED) PHASE2 Published literature Clinical trial publication A device for overcoming discoordination with metered-dose inhalers (The Journal of allergy and clinical immunology, 1993) Clinical trial publication Comparative effects of pirbuterol acetate, metaproterenol, and placebo aerosols on pulmonary function and incidence of cardiac ectopy (The Journal of asthma : official journal of the Association for the Care of Asthma, 1989) Clinical trial publication Acute bronchial and cardiovascular effects of increasing doses of pirbuterol acetate aerosol in asthma (Annals of allergy, 1982) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
PREDNISOLONE SODIUM PHOSPHATE	Small molecule	Approved	Strong	100	8 trials 1 Trial pubs 1 RCT View evidence Registry trials NCT04874610 — Steroid Metabolism in Obese and Non-Obese Pediatric Patients Hospitalized for Status Asthmaticus (COMPLETED) NCT03133897 — Dexamethasone Versus Prednisone for Asthma Treatment in the Pediatric Inpatient Population; a Feasibility Study (TERMINATED) PHASE3 NCT06171932 — Comparison Of Efficacy Of Hydrocortisone And Methyl Prednisolone In Acute Severe Asthma (UNKNOWN) NCT01615874 — Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574) (WITHDRAWN) PHASE2 NCT01326494 — Reducing the Acute Care Burden of Childhood Asthma on Health Services in British Columbia (COMPLETED) PHASE4 NCT04276233 — Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma (COMPLETED) PHASE4 NCT05850143 — EFFECTIVENESS OF SINGLE DOSE ORAL DEXAMETHASONE VERSUS MULTIDOSE PREDNISOLONE FOR TREATMENT OF ACUTE EXACERBATIONS OF ASTHMA AMONG CHILDREN ATTENDING THE EMERGENCY DEPARTMENT OF CHILDREN HOSPITAL, ISLAMABAD (UNKNOWN) NA NCT00971893 — A Study To Assess The Safety And Effectiveness Of Medrol® In Acute Asthma In Indian Patients (WITHDRAWN) Published literature Clinical trial publication Prednisolone oral solution plus inhaled procaterol for acute asthma in children: a double-blind randomized controlled trial (Acta paediatrica Taiwanica = Taiwan er ke yi xue hui za zhi, 2007) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
PREDNISONE	Small molecule	Approved	Strong	100	8 trials 11 Cochrane 15 Meta-analysis 222 Trial pubs 163 RCT View evidence Registry trials NCT05035862 — Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma (TERMINATED) PHASE1 NCT06833814 — DOSE Trial: Optimal Dose of Oral Corticosteroids to Treat Asthma Exacerbations (NOT_YET_RECRUITING) PHASE4 NCT03133897 — Dexamethasone Versus Prednisone for Asthma Treatment in the Pediatric Inpatient Population; a Feasibility Study (TERMINATED) PHASE3 NCT00377364 — Acetaminophen (Tylenol) for Mood and Memory Changes Associated With Corticosteroid Therapy (COMPLETED) PHASE4 NCT03470311 — Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies (COMPLETED) PHASE3 NCT01615874 — Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574) (WITHDRAWN) PHASE2 NCT01621386 — Ventilatory Heterogeneity in Participants With Asthma (MK-0476-513) (COMPLETED) PHASE1 NCT01326494 — Reducing the Acute Care Burden of Childhood Asthma on Health Services in British Columbia (COMPLETED) PHASE4 Published literature Cochrane review The efficacy of dexamethasone compared to prednisone/prednisolone for the management of pediatric patients with acute exacerbation of asthma: a systematic review and meta-analysis (The Journal of asthma : official journal of the Association for the Care of Asthma, 2025) Cochrane review Dexamethasone versus prednisone/prednisolone in the management of pediatric patients with acute asthmatic exacerbations: a systematic review and meta-analysis (The Journal of asthma : official journal of the Association for the Care of Asthma, 2023) Cochrane review Safety of corticosteroids in young children with acute respiratory conditions: a systematic review and meta-analysis (BMJ open, 2019) Cochrane review Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for acute asthma (The Cochrane database of systematic reviews, 2018) Cochrane review Effects of prednisone on eosinophilic bronchitis in asthma: a systematic review and meta-analysis (Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia, 2014) Meta-analysis Dexamethasone Versus Prednisone or Prednisolone for Acute Pediatric Asthma Exacerbations in the Emergency Department: A Meta-Analysis (Pediatric emergency care, 2021) Meta-analysis Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma (The European respiratory journal, 2020) Clinical trial publication Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trial (The Lancet. Respiratory medicine, 2026) Clinical trial publication Modification of asthma treatment efficacy by healthcare access: A reanalysis of AsthmaNet Step-Up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations (STICS) clinical trial (Respiratory medicine, 2024) Clinical trial publication The Glucocorticoid Toxicity Index-Metabolic Domains, an abridged version of the Glucocorticoid Toxicity Index: post-hoc analysis of data from the ADVOCATE trial (The Lancet. Rheumatology, 2023) Clinical trial publication As-Needed Use of Short-Acting β(2)-Agonists Alone Versus As-Needed Use of Short-Acting β(2)-Agonists Plus Inhaled Corticosteroids in Pediatric Patients With Mild Intermittent (Step 1) Asthma: A Cost-Effectiveness Analysis (The journal of allergy and clinical immunology. In practice, 2022) Clinical trial publication Patient Advocates for Low-Income Adults with Moderate to Severe Asthma: A Randomized Clinical Trial (The journal of allergy and clinical immunology. In practice, 2020) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
SALMETEROL XINAFOATE	Small molecule	Approved	Strong	100	8 trials 2 Cochrane 4 Meta-analysis 44 Trial pubs 41 RCT View evidence Registry trials NCT02388373 — A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down (COMPLETED) PHASE4 NCT00529529 — Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma (COMPLETED) PHASE3 NCT00200967 — Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE) (COMPLETED) PHASE3 NCT05459194 — Efficacy and Safety Study of Fluticasone/Salmeterol Administered With Elpenhaler (COMPLETED) NA NCT00364442 — Repeat Dose Study of Fluticasone Propionate/Salmeterol Versus Fluticasone Propionate + Salmeterol In Asthmatics (COMPLETED) PHASE1 NCT02251379 — Environmental Control as Add-on Therapy in Childhood Asthma (COMPLETED) PHASE2 NCT00169546 — Study In Airway Physiology In Children SERETIDE DISKUS ® Inhlaer and FLIXOTIDE® Inhaler Are Trademarks of GSK Group of Companies. (COMPLETED) PHASE4 NCT00452348 — A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma (COMPLETED) PHASE4 Published literature Cochrane review Inhaled long acting beta agonists for stable chronic asthma (The Cochrane database of systematic reviews, 2003) Cochrane review Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma (The Cochrane database of systematic reviews, 2002) Meta-analysis COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada (Respiratory medicine, 2014) Meta-analysis Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma (Current medical research and opinion, 2007) Meta-analysis Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids (MedGenMed : Medscape general medicine, 2001) Systematic review Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol (Clinical therapeutics, 2009) Clinical trial publication Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study (The Lancet. Respiratory medicine, 2020) Clinical trial publication The efficacy and safety of fluticasone/salmeterol compared to fluticasone in children younger than four years of age (Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2019) Clinical trial publication Video education versus face-to-face education on inhaler technique for patients with well-controlled or partly-controlled asthma: A phase IV, open-label, non-inferiority, multicenter, randomized, controlled trial (PloS one, 2018) Clinical trial publication Pharmacokinetic analysis of inhaled salmeterol in asthma patients: Evidence from two dry powder inhalers (Biopharmaceutics & drug disposition, 2017) Clinical trial publication A Randomized Pragmatic Trial of Changing to and Stepping Down Fluticasone/Formoterol in Asthma (The journal of allergy and clinical immunology. In practice, 2017) Randomized controlled trial Clinical Bioequivalence of OT329 SOLIS and ADVAIR DISKUS in Adults with Asthma (Annals of the American Thoracic Society, 2017) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
TIOTROPIUM BROMIDE	Small molecule	Approved	Strong	100	8 trials 3 Cochrane 1 Meta-analysis 7 Trial pubs 7 RCT View evidence Registry trials NCT06609941 — Additive Effects of Alternative Nostril Breathing with Pharmacological Management on Dyspnea and Control Pause in Patients with Bronchial Asthma (RECRUITING) NA NCT02682862 — Ultra-long Acting Bronchodilator Therapy in Smoking Asthmatics (COMPLETED) PHASE4 NCT01152450 — A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma (COMPLETED) PHASE2 NCT01316380 — Efficacy and Safety of 2 Doses of Tiotropium Via Respimat in Adult Patients With Mild Persistent Asthma (COMPLETED) PHASE3 NCT01634113 — Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma (COMPLETED) PHASE2 NCT02489981 — Specific Use-result Surveillance of Spiriva Respimat in Asthmatics (COMPLETED) NCT01172821 — Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II (COMPLETED) PHASE3 NCT00557700 — Study to Investigate the Effect of Inhaled Tiotropium Bromide on Neurokinin-A Induced Bronchoconstriction in Patients With Mild-to-moderate Asthma (COMPLETED) PHASE2 Published literature Cochrane review Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma (The Cochrane database of systematic reviews, 2016) Cochrane review Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma (The Cochrane database of systematic reviews, 2015) Cochrane review Anticholinergic agents for chronic asthma in adults (The Cochrane database of systematic reviews, 2004) Systematic review Tiotropium in the management of paediatric and adolescent asthma: Systematic review (Paediatric respiratory reviews, 2021) Systematic review Efficacy and safety of tiotropium in school-age children with moderate-to-severe symptomatic asthma: A systematic review (Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2017) Clinical trial publication Inhaled Glucocorticoid with or without Tiotropium Bromide for Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome (Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2019) Clinical trial publication Therapeutic Effects of a Long-Acting Cholinergic Receptor Blocker, Tiotropium Bromide, on Asthma (Medical science monitor : international medical journal of experimental and clinical research, 2018) Clinical trial publication Predictors of response to tiotropium versus salmeterol in asthmatic adults (The Journal of allergy and clinical immunology, 2013) Clinical trial publication Tiotropium bromide step-up therapy for adults with uncontrolled asthma (The New England journal of medicine, 2010) Clinical trial publication Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma (Chest, 2005) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
VILANTEROL TRIFENATATE	Small molecule	Approved	Strong	100	6 trials 4 Trial pubs 4 RCT View evidence Registry trials NCT01498653 — Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry (COMPLETED) PHASE3 NCT04265105 — Fluticasone-Vilanterol Once Daily Dose for the Treatment of Mild Asthma in Adults (COMPLETED) PHASE2, PHASE3 NCT03378648 — A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366 (COMPLETED) PHASE1, PHASE2 NCT06372496 — Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma (ACTIVE_NOT_RECRUITING) PHASE4 NCT03184987 — A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma (COMPLETED) PHASE3 NCT01498679 — Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry. (COMPLETED) PHASE3 Published literature Clinical trial publication Metabolomic changes related to airway inflammation, asthma pathogenesis and systemic activity following inhaled fluticasone furoate/vilanterol: a randomized controlled trial (Respiratory research, 2022) Clinical trial publication Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trial (Respiratory research, 2018) Clinical trial publication 24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids (The European respiratory journal, 2012) Clinical trial publication Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial (Thorax, 2012) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ZAFIRLUKAST	Small molecule	Approved	Strong	100	—	Open Targets, ChEMBL	ChEMBL Open Targets
ASPIRIN	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
AZITHROMYCIN	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
CHOLECALCIFEROL	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
CLARITHROMYCIN	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
COLCHICINE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ERGOCALCIFEROL	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
LEBRIKIZUMAB	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
LEVOCETIRIZINE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
LORATADINE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
METHOTREXATE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
NEDOCROMIL	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
TELITHROMYCIN	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
UMECLIDINIUM	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ABLUKAST	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ACETAMINOPHEN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ATAPROST	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ATEZOLIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ATRELEUTON	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE DIPROPIONATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE SODIUM PHOSPHATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BIOTIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BROXATEROL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CARNITINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CHEMBL282468	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
DESLORATADINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DEXPRAMIPEXOLE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DOXOFYLLINE	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
DURVALUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FENOTEROL	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
FEVIPIPRANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FEXOFENADINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FISH OIL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FLUTICASONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FOROPAFANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FOSFRUCTOSE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FRENESLERBART	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GUSELKUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HUMAN IMMUNOGLOBULIN G	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IBUPROFEN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ICOSAPENT	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
INDACATEROL	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
INDACATEROL ACETATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INFLIXIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
INSULIN HUMAN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IPRATROPIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ISRAPAFANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LANSOPRAZOLE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LENERCEPT	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LEVOCARNITINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MAGNESIUM SULFATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MASITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MEVONLERBART	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OCANKITUG	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PEMBROLIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PUMACTANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
QUINOTOLAST	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RABEPRAZOLE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RIVIPANSEL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RIVIPANSEL SODIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ROFLUMILAST	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
SETIPIPRANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SIMVASTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TIMAPIPRANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TIOTROPIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TISLELIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRALOKINUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRIAMCINOLONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRIAMCINOLONE HEXACETONIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
UMECLIDINIUM BROMIDE	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
VELIFLAPON	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VILANTEROL	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
ZINC SULFATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ALENDRONIC ACID	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
AMBRISENTAN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
AMELUBANT	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ANRUKINZUMAB	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ANTIPYRINE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ARGININE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
BENZOCAINE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
BOSENTAN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
BRODALUMAB	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
CLAZAKIZUMAB	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
DOCONEXENT	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ENOKIZUMAB	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
FIBOFLAPON	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
GALLOPAMIL	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
IMATINIB MESYLATE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
INDACATEROL MALEATE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ITRACONAZOLE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
MINOCYCLINE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
NADOLOL	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
OLODATEROL	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
OXELUMAB	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SECUKINUMAB	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SEMAGLUTIDE	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SIRUKUMAB	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SITAXENTAN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SODIUM NITRITE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
TERFENADINE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
TOFIMILAST	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
VIDUPIPRANT	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ABATACEPT	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ABEDITEROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ACLOPROXALAP	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ACREOZAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ADALIMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ADC3680	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ADERAMASTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AMLITELIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AMPHOTERICIN B	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANTI-PSGL-1 ANTIBODY SELK2	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANTIMONY	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ARFORMOTEROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ASM-024	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ASTEGOLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ATORVASTATIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ATULIFLAPON	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZD-5423	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZD-7624	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZD-8154	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZD-8848	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZD1981	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZD3199	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AZX-100	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BAMAQUIMAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BAVITUXIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BEDORADRINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BEDORADRINE SULFATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BI-671800	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BIMOSIAMOSE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BREPOCITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BUTIXOCORT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CARMOTEROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CAVOSONSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CEP-1347	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHEMBL1082	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1922673	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL279597	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL3301673	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL361812	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL773	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL777	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CJM-112	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CLOPIDOGREL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CURCUMIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DACLIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DARBUFELONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DEFLAZACORT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DELGOCITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DEURUXOLITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DORNASE ALFA	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DOXYCYCLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DUVAKITUG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DUVELISIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ECULIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ELAREKIBEP	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ENSIFENTRINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ESOMEPRAZOLE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ETANERCEPT	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ETOKIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FINGOLIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FLEZELASTINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FREVECITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GAMMA-TOCOPHEROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GEFAPIXANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GEMILUKAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GOLIMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GSK-2245035	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GSK-2269557	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GSK-256066	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GSK159802	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GW-274150	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GW-870086	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HT-0712	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IMATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IMITRODAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INCOMPLETE FREUND'S ADJUVANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INULIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IRALUKAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ISBUFYLLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ISOSPAGLUMIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ITEPEKIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
JNJ-39758979	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
JNJ-49095397	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
L-CITRULLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
L-NAME	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LAROPIPRANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LAZUCIRNON	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LENZILUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LEVOFLOXACIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LIGELIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LONDAMOCITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LUNSEKIMIG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MEDIUM-CHAIN TRIGLYCERIDES	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MELRILIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MEQUITAMIUM IODIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METFORMIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
METHOXYVERAPAMIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MILVETEROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MK-1029	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
N6022	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NAFAGREL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NAVARIXIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NEMIRALISIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NOBERASTINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NOLPITANTIUM BESILATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OGLEMILAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ONTAZOLAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OXITRIPTAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OXYGEN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PALIFERMIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PASCOLIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PBF-680	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEMIROLAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PF-00610355	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PF-03715455	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PF-4191834	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PICUMETEROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIOGLITAZONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIOGLITAZONE HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIRODOMAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PITRAKINRA	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PL-3994	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
POVORCITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PRASTERONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PROCATEROL HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PROPRANOLOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PUMAFENTRINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
QAV680	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
QAX-576	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
QUIFLAPON SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
QUILIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
QUISOVALIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
R-343	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
REMIBRUTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
REVAMILAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RILZABRUTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RISANKIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RITLECITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ROCATINLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ROSIGLITAZONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SENICAPOC	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SETILEUTON	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SILYMARIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SODIUM CHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SODIUM NITRATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SOLRIKITUG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SR-2640	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
STAPOKIBART	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SULUKAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TACROLIMUS	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TACROLIMUS ANHYDROUS	Small molecule	Phase II	Emerging	60	3 trials View evidence Registry trials NCT00189722 — Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma (COMPLETED) PHASE2 NCT00116103 — A Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent Asthma (COMPLETED) PHASE2 NCT00189787 — Dose Response of Inhaled Tacrolimus in Patients With Moderate Persistent Asthma (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
TC-6987	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEPOXALIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TETRAZOLAST MEGLUMINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
THR-18	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIBENELAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TILREKIMIG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIPELUKAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TOREFORANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TOREFORANT TARTRATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TOZORAKIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TPI-1020	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRANIMILAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TREBANANIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TREGALIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRIGLYCERIDES, MEDIUM-CHAIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TROMETHAMINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VALATEGRAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VALATEGRAST HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VAPENDAVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VAROKIBART	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VELSECORAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VEREKITUG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZD-2138	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GAMOLENIC ACID	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
ILOPROST	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
INDOMETHACIN	Small molecule	Phase I	Emerging	40	1 trials 31 Trial pubs 18 RCT View evidence Registry trials NCT01733485 — Electrophilic Fatty Acid Derivatives in Asthma (COMPLETED) PHASE1 Published literature Clinical trial publication Effect of inhaled indomethacin in asthmatic patients taking high doses of inhaled corticosteroids (The Journal of allergy and clinical immunology, 2000) Clinical trial publication Allergen-induced synthesis of F(2)-isoprostanes in atopic asthmatics. Evidence for oxidant stress (American journal of respiratory and critical care medicine, 1999) Clinical trial publication Different effects of inhaled aspirinlike drugs on allergen-induced early and late asthmatic responses (American journal of respiratory and critical care medicine, 1999) Clinical trial publication Inhibitory effect of indomethacin on tachyphylaxis in response to acetaldehyde-induced bronchoconstriction in patients with asthma (The Journal of allergy and clinical immunology, 1997) Clinical trial publication Effect of inhaled frusemide and oral indomethacin on the airway response to hypertonic saline challenge in asthmatic subjects (Thorax, 1997) Randomized controlled trial Effect of inhaled indomethacin on exercise-induced bronchoconstriction in children with asthma (American journal of respiratory and critical care medicine, 1997) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
LOVASTATIN	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
LOXAPINE	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
MOGAMULIZUMAB	Biologic	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
VORICONAZOLE	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
ADRIFORANT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AM-211	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AMBROXOL ACEFYLLINATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ANAKINRA	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
APOCYNIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BITS-7201A	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CENDAKIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CHEMBL1009	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1200748	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL146	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL196	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL32	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL3989727	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL661	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
COMEKIBART	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CYSTEAMINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DESOXYRIBONUCLEASE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GINGER	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GINKGO	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GRC-6211	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GS 6201	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GSK-2239633	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GSK-679586A	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IMA-026	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ITOLIZUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LACTOBACILLUS ACIDOPHILUS	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LANINAMIVIR OCTANOATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LAS190792	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
LINOLEIC ACID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MAGNESIUM STEARATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MEDI-4212	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MITOQUINOL CATION	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NAVAFENTEROL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PF-5212372	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PYRUVATE SODIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RESOLVIN E1	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RG-7152	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RG6341	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RG7185	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TAUROLITHOCHOLIC ACID	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VEPALIMOMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VP-14637	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ZAVEGEPANT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
(R)-(+)-Zileuton	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ACLIDINIUM BROMIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ALBUTEROL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ASOBAMAST	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ATL-844	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BAMBUTEROL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BECLOMETHASONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BENRALIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BITOLTEROL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CHYMOTRYPSIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CINALUKAST	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CITALOPRAM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CLINPROST	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CROMOLYN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CV-6209	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEPEMOKIMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEXAMETHASONE PHOSPHORIC ACID	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DUPILUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
EFIPLADIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ENPROFYLLINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
EPHEDRINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
EPHEDRINE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ESCITALOPRAM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ETORICOXIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FENSPIRIDE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FLUPREDNISOLONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FLUTICASONE FUROATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FORMOTEROL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FPL-55712	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GEMCITABINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GLYCEROL, IODINATED	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GLYCOPYRRONIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GLYCOPYRRONIUM BROMIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GLYCOPYRRONIUM TOSYLATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
HYDROCORTISONE SODIUM SUCCINATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ICI-198615	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
IPRATROPIUM BROMIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ISOETHARINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ISOMAZOLE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
KHELLIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
KRYPTON KR 81M	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
L-648051	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LAS101057	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LEVALBUTEROL HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LEVOSALBUTAMOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LODOXAMIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LY-255283	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MANNITOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MEPOLIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METAPROTERENOL SULFATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METHACHOLINE CHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MIDAGLIZOLE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MOMETASONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MONTELUKAST	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NAVAFENTEROL SACCHARINATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
OMALIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
OXITROPIUM BROMIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PIMAGEDINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PIRBUTEROL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PIRMAGREL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PRANLUKAST	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PREDNISOLONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PROCATEROL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PROTOKYLOL HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
REPIRINAST	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RESLIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RIMITEROL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RO-201724	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SALMETEROL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SOY ISOFLAVONES	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SULFORAPHANE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SULOCHRIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SULOTROBAN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TALAROZOLE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TERBUTALINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TERBUTALINE SULFATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TEZEPELUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
THEOBROMINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
THEOPHYLLINE	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TOMELUKAST	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TRIAMCINOLONE ACETONIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ZILEUTON	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ACETAZOLAMIDE Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ADENOSINE Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
ALFUZOSIN Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
ALFUZOSIN HYDROCHLORIDE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMINOPHYLLINE Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
AMIODARONE HYDROCHLORIDE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
AMITRIPTYLINE HYDROCHLORIDE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
AMPHETAMINE Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
APOMORPHINE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
APRACLONIDINE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
APRACLONIDINE HYDROCHLORIDE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ASENAPINE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
ASPIRIN Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	DGIdb	—
ATENOLOL Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
ATIPAMEZOLE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
ATROPINE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
BENZPHETAMINE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
BETHANIDINE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BRIMONIDINE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
BRIMONIDINE TARTRATE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BROMOCRIPTINE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
CABERGOLINE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
CAFFEINE Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
CAFFEINE CITRATE Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CARVEDILOL Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
CARVEDILOL PHOSPHATE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
CELIPROLOL Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLORPROMAZINE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
CIPROFLOXACIN Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLOMIPRAMINE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOMIPRAMINE Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLONIDINE HYDROCHLORIDE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOZAPINE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
CYPROHEPTADINE HYDROCHLORIDE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
DAPIPRAZOLE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
DAPIPRAZOLE HYDROCHLORIDE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DEBRISOQUIN Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
DEFIBROTIDE Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
DEXMEDETOMIDINE HYDROCHLORIDE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
DEXTROAMPHETAMINE SULFATE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
DIAZEPAM Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIPIVEFRIN Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
DIPIVEFRIN HYDROCHLORIDE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DISULFIRAM Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
DOPAMINE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
DOXAZOSIN MESYLATE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
DOXAZOSIN MESYLATE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DRONEDARONE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
DROXIDOPA Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
EPHEDRINE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
EPHEDRINE HYDROCHLORIDE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
EPHEDRINE SULFATE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
EPINEPHRINE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
EPINEPHRINE BITARTRATE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
EPIRUBICIN Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ERGOLOID MESYLATES Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ERGOLOID MESYLATES, USP Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
ERGOTAMINE Repurposing via ADRA1D	Small molecule	Approved	Strong	95	—	DGIdb	—
ERGOTAMINE TARTRATE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ETHOXZOLAMIDE Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ETOMIDATE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
FENOLDOPAM Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
FLAVONE Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUMAZENIL Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
GUANABENZ Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
GUANABENZ ACETATE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
GUANFACINE HYDROCHLORIDE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
GUANFACINE HYDROCHLORIDE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
HYDROXYAMPHETAMINE HYDROBROMIDE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ILOPERIDONE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
IMIPRAMINE Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDOMETHACIN Repurposing via ADORA1	Small molecule	Approved	Strong	95	1 trials 31 Trial pubs 18 RCT View evidence Registry trials NCT01733485 — Electrophilic Fatty Acid Derivatives in Asthma (COMPLETED) PHASE1 Published literature Clinical trial publication Effect of inhaled indomethacin in asthmatic patients taking high doses of inhaled corticosteroids (The Journal of allergy and clinical immunology, 2000) Clinical trial publication Allergen-induced synthesis of F(2)-isoprostanes in atopic asthmatics. Evidence for oxidant stress (American journal of respiratory and critical care medicine, 1999) Clinical trial publication Different effects of inhaled aspirinlike drugs on allergen-induced early and late asthmatic responses (American journal of respiratory and critical care medicine, 1999) Clinical trial publication Inhibitory effect of indomethacin on tachyphylaxis in response to acetaldehyde-induced bronchoconstriction in patients with asthma (The Journal of allergy and clinical immunology, 1997) Clinical trial publication Effect of inhaled frusemide and oral indomethacin on the airway response to hypertonic saline challenge in asthmatic subjects (Thorax, 1997) Randomized controlled trial Effect of inhaled indomethacin on exercise-induced bronchoconstriction in children with asthma (American journal of respiratory and critical care medicine, 1997) CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
ISOPROTERENOL Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
ISOSORBIDE DINITRATE Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ISTRADEFYLLINE Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
LABETALOL Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
LABETALOL HYDROCHLORIDE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
LEVODOPA Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
LEVONORDEFRIN Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
LISDEXAMFETAMINE DIMESYLATE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
LOFEXIDINE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
LOFEXIDINE HYDROCHLORIDE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
LURASIDONE HYDROCHLORIDE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
MAFENIDE Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MECAMYLAMINE Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MEFLOQUINE Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
MEPERIDINE HYDROCHLORIDE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
MEPHENTERMINE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
MEPHENTERMINE SULFATE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METARAMINOL Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
METARAMINOL BITARTRATE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METHAMPHETAMINE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
METHAZOLAMIDE Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHOTRIMEPRAZINE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
METHOXAMINE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
METHOXAMINE HYDROCHLORIDE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METHOXSALEN Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHYLDOPA ANHYDROUS Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
METHYLDOPATE HYDROCHLORIDE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METOPROLOL Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METOPROLOL SUCCINATE Repurposing via ADRA1D	Small molecule	Approved	Strong	95	—	DGIdb	—
MIANSERIN Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIDODRINE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
MIDODRINE HYDROCHLORIDE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
MILNACIPRAN Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
MIRTAZAPINE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
MODAFINIL Repurposing via ADRA1D	Small molecule	Approved	Strong	95	—	DGIdb	—
MOXISYLYTE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
MOXONIDINE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
NAFTOPIDIL Repurposing via ADRA1D	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NALIDIXIC ACID Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NAPHAZOLINE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
NAPHAZOLINE HYDROCHLORIDE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NEFAZODONE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
NICARDIPINE Repurposing via ADORA3	Small molecule	Approved	Strong	95	—	DGIdb	—
NICOTINE Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NIFEDIPINE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
NOREPINEPHRINE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
NOREPINEPHRINE BITARTRATE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NORFLOXACIN Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NORTRIPTYLINE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
OFLOXACIN Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OLANZAPINE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
OXTRIPHYLLINE Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
OXYMETAZOLINE HYDROCHLORIDE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
OXYMETAZOLINE HYDROCHLORIDE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
PAPAVERINE Repurposing via ADRA1D	Small molecule	Approved	Strong	95	—	DGIdb	—
PENTOXIFYLLINE Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
PERGOLIDE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENDIMETRAZINE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENOXYBENZAMINE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENOXYBENZAMINE HYDROCHLORIDE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENTOLAMINE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENTOLAMINE MESYLATE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENYLEPHRINE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENYLEPHRINE BITARTRATE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENYLEPHRINE HYDROCHLORIDE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENYLPROPANOLAMINE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENYLPROPANOLAMINE HYDROCHLORIDE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENYLPROPANOLAMINE POLISTIREX Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PHENYTOIN Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PRAZOSIN Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
PRAZOSIN Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PRAZOSIN HYDROCHLORIDE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PROMAZINE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
PROPIOMAZINE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
PSEUDOEPHEDRINE POLISTIREX Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
QUETIAPINE FUMARATE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
RACEPINEPHRINE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
RAUWOLFIA SERPENTINA Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
RAUWOLFIA SERPENTINA (USP) Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
REGADENOSON Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
REGADENOSON ANHYDROUS Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
REMIFENTANIL HYDROCHLORIDE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
RISPERIDONE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
SERTINDOLE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
SILODOSIN Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
SIROLIMUS Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
SODIUM CHLORIDE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
SULBACTAM Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TACROLIMUS ANHYDROUS Repurposing via ADORA1	Small molecule	Approved	Strong	95	3 trials View evidence Registry trials NCT00189722 — Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma (COMPLETED) PHASE2 NCT00116103 — A Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent Asthma (COMPLETED) PHASE2 NCT00189787 — Dose Response of Inhaled Tacrolimus in Patients With Moderate Persistent Asthma (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
TAMSULOSIN HYDROCHLORIDE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
TAMSULOSIN HYDROCHLORIDE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TAZOBACTAM Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TERAZOSIN Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
TERAZOSIN HYDROCHLORIDE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TETRAHYDROZOLINE HYDROCHLORIDE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
THEOPHYLLINE Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
THEOPHYLLINE Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
THEOPHYLLINE SODIUM GLYCINATE Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
THIORIDAZINE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
TIZANIDINE HYDROCHLORIDE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TIZANIDINE HYDROCHLORIDE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
TOLAZOLINE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
TOLAZOLINE HYDROCHLORIDE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TRAZODONE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
TRIFLUOPERAZINE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
TRIMIPRAMINE MALEATE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TROGLITAZONE Repurposing via ADORA1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
VIDARABINE Repurposing via ADORA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
XYLAZINE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
XYLOMETAZOLINE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
XYLOMETAZOLINE HYDROCHLORIDE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
YOHIMBINE Repurposing via ADRA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
ZIPRASIDONE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
DARAPLADIB Repurposing via ADORA1	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
FENRETINIDE Repurposing via ADORA1	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
ALPRENOLOL Repurposing via ADORA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
AMIFLOXACIN Repurposing via ADORA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
BROLAMFETAMINE Repurposing via ADORA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
CARZENIDE Repurposing via ADORA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIFLOXACIN Repurposing via ADORA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIMECAMINE Repurposing via ADORA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ELLAGIC ACID Repurposing via ADORA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ENISOPROST Repurposing via ADORA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FENCAMFAMIN Repurposing via ADORA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FLEROXACIN Repurposing via ADORA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
IDOXIFENE Repurposing via ADORA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
LYSERGIDE Repurposing via ADORA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
MERAFLOXACIN Repurposing via ADORA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
TENAMFETAMINE Repurposing via ADORA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ZIDAPAMIDE Repurposing via ADORA1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets

Natural Products

128 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked). Only agents with direct clinical evidence are shown by default.

Reference lookups: Examine.com

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
Probiotics Natural product Cochrane review Gut microbiome dysbiosis in chronic lung disease: a systematic review a… Cochrane review Probiotics in infants for prevention of allergic disease Cochrane review Effect of dietary interventions on markers of type 2 inflammation in as…	Probiotic	Approved	Moderate	26	8 trials 14 Cochrane 15 Meta-analysis 21 Trial pubs 18 RCT View evidence Registry trials NCT03021161 — The Effect of Probiotics on Asthma Risk in Animal Laboratory Workers (UNKNOWN) PHASE4 NCT01123252 — Seasonal Allergic Rhinitis Study (COMPLETED) PHASE2 NCT00490425 — Prevention of Asthma and Allergy by Probiotic Lactobacillus GG (COMPLETED) PHASE4 NCT00159523 — Impact in Off-spring of Mothers After Perinatal Daily Intake of a Probiotic (COMPLETED) NA NCT05949255 — Probiotics and Insulin Resistance in Obese Asthmatics (ACTIVE_NOT_RECRUITING) NA NCT00325273 — Prevention Allergic Disease of Infant With Probiotics During Pregnancy and Neonatal Period (COMPLETED) PHASE3 NCT00852124 — Safety of VSL#3 in Adult Asthmatics (TERMINATED) PHASE1, PHASE2 NCT01366222 — Food Concentrates Supplementation to Alleviate Asthma in Children (COMPLETED) NA Published literature Cochrane review Gut microbiome dysbiosis in chronic lung disease: a systematic review and meta-analysis (Frontiers in cellular and infection microbiology, 2025) Cochrane review Probiotics in infants for prevention of allergic disease (The Cochrane database of systematic reviews, 2025) Cochrane review Effect of dietary interventions on markers of type 2 inflammation in asthma: A systematic review (Respiratory medicine, 2024) Cochrane review Effects of Early Diet on the Prevalence of Allergic Disease in Children: A Systematic Review and Meta-Analysis (Advances in nutrition (Bethesda, Md.), 2024) Cochrane review Treating asthma patients with probiotics: a systematic review and meta-analysis (Nutricion hospitalaria, 2023) Meta-analysis A Meta-Analysis of Probiotics for the Treatment of Allergic Airway Diseases in Children and Adolescents (American journal of rhinology & allergy, 2022) Clinical trial publication Synbiotic Bactecal® reduces airway obstruction, sputum eosinophils and IL-4 but increases sputum IL-8 in patients with uncontrolled asthma (Cytokine, 2026) Clinical trial publication Multistrain Probiotics Supplement Alleviates Asthma Symptoms via Increasing Treg Cells Population: A Randomized, Double-Blind, Placebo-Controlled Trial (International archives of allergy and immunology, 2023) Clinical trial publication The impact of multistrains of probiotics on Th17-related cytokines in patients with asthma: a randomized, double-blind, placebo-controlled trial (The Journal of asthma : official journal of the Association for the Care of Asthma, 2023) Clinical trial publication Adjunctive Probiotics Alleviates Asthmatic Symptoms via Modulating the Gut Microbiome and Serum Metabolome (Microbiology spectrum, 2021) Clinical trial publication The Impact of Formula Choice for the Management of Pediatric Cow's Milk Allergy on the Occurrence of Other Allergic Manifestations: The Atopic March Cohort Study (The Journal of pediatrics, 2021) Randomized controlled trial Efficacy of Lactobacillus Administration in School-Age Children with Asthma: A Randomized, Placebo-Controlled Trial (Nutrients, 2018) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov, Examine.com	Examine.com
Vitamin D3 Natural product Cochrane review Vitamin D supplementation decrease asthma exacerbations in children: a… Cochrane review Vitamin D for the management of asthma Meta-analysis Prenatal vitamin D supplementation reduces risk of asthma/recurrent whe…	Nutraceutical	Phase III	Moderate	20	8 trials 2 Cochrane 3 Meta-analysis 22 Trial pubs 20 RCT View evidence Registry trials NCT01432678 — Vitamin D Status in Pediatric Asthma (COMPLETED) NCT00856947 — Vitamin D Supplementation During Pregnancy for Prevention of Asthma in Childhood (ACTIVE_NOT_RECRUITING) PHASE1 NCT02880930 — Optimizing Vitamin D Status in Children With Wheeze / Asthma (OPTIVIT) (COMPLETED) NA NCT03880734 — This Study Include Asthma Chronic Obstructive Pulmonary Disease (COPD) Overlap Patients.Patients Were Vitamin D Deficient.Age Range 40-70 Years, Smokers.Patients Were Advised to Take Either Placebo or Vitamin D3.Lung Functions and Exercise Tolerance Were Assessed at Baseline and at 26th Weeks. (COMPLETED) PHASE2 NCT03773809 — Impact of Vitamin D3 Administration on Cardiac Autonomic Tone in Asthma Chronic Obstructive Pulmonary Disease(COPD) Overlap Patients (COMPLETED) NA NCT02197702 — Vitamin D in Preschoolers With Viral-induced Asthma (COMPLETED) PHASE2, PHASE3 NCT01234909 — Asthma, Missed Immunizations, and Vitamin D Deficiency in Atopic Dermatitis (TERMINATED) NCT04179461 — Personalized Treatment Algorithms for Difficult-to-treat Asthma (COMPLETED) PHASE2 Published literature Cochrane review Vitamin D supplementation decrease asthma exacerbations in children: a systematic review and meta-analysis of randomized controlled trials (Annals of medicine, 2024) Cochrane review Vitamin D for the management of asthma (The Cochrane database of systematic reviews, 2023) Meta-analysis Prenatal vitamin D supplementation reduces risk of asthma/recurrent wheeze in early childhood: A combined analysis of two randomized controlled trials (PloS one, 2017) Systematic review Nutritional Interventions to Improve Asthma-Related Outcomes through Immunomodulation: A Systematic Review (Nutrients, 2020) Clinical trial publication Exploratory pilot trial of a multicomponent immunonutritional supplement in children with allergic asthma and rhinitis: The INAPRA study (International immunopharmacology, 2026) Clinical trial publication Does Vitamin D₃ Supplementation Improve Cardiac Autonomic Nerve Function in Vitamin D₃ Deficient Asthma COPD Overlap (ACO) Patients? A Randomized Clinical Trial (Mymensingh medical journal : MMJ, 2025) Clinical trial publication Effect of age and body mass index on vitamin D level in children with asthma in Riyadh (Scientific reports, 2021) Clinical trial publication Effect of Monthly Vitamin D Supplementation on Preventing Exacerbations of Asthma or Chronic Obstructive Pulmonary Disease in Older Adults: Post Hoc Analysis of a Randomized Controlled Trial (Nutrients, 2021) Clinical trial publication Effect of Vitamin D3 Supplementation on Severe Asthma Exacerbations in Children With Asthma and Low Vitamin D Levels: The VDKA Randomized Clinical Trial (JAMA, 2020) Randomized controlled trial Association of serum 25-OH vitamin D₃ with serum IgE and the Pediatric Asthma Severity Score in patients with pediatric asthma (Allergy and asthma proceedings, 2020) CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Magnesium Natural product Meta-analysis Intravenous Bronchodilators in Pediatric Critical Asthma: A Systematic… Meta-analysis Use of intravenous magnesium sulfate in addition to standard first-line… Meta-analysis Second-line treatment option for children aged 18 years and under with…	Nutraceutical	Phase III	Moderate	20	8 trials 26 Meta-analysis 94 Trial pubs 84 RCT View evidence Registry trials NCT03296579 — Non-invasive Ventilation vs. Standard Therapy for Children Hospitalized With an Acute Exacerbation of Asthma (UNKNOWN) NA NCT06626620 — Randomized Controlled Trial of Intravenous Magnesium Sulfate Versus Terbutaline for Children in the Management of Acute Exacerbation of Asthma (COMPLETED) PHASE3 NCT01856959 — Lung Function Changes of Induced Asthma Children Treated With Inhaled MgSO4 (COMPLETED) NA NCT01209026 — Corrected QT (QTc) Study With Flucticasone Furoate and GW642444 (COMPLETED) PHASE1 NCT03880734 — This Study Include Asthma Chronic Obstructive Pulmonary Disease (COPD) Overlap Patients.Patients Were Vitamin D Deficient.Age Range 40-70 Years, Smokers.Patients Were Advised to Take Either Placebo or Vitamin D3.Lung Functions and Exercise Tolerance Were Assessed at Baseline and at 26th Weeks. (COMPLETED) PHASE2 NCT02135718 — ELLIPTA™ vs. MDI Inhaler Preference Study, in Adult Subjects With Asthma (COMPLETED) NCT05166811 — Timely Intravenous Magnesium for Asthma in Children (COMPLETED) PHASE2 NCT01113138 — Study of the Metabolism of Two Magnesium Supplements in Healthy Volunteers (COMPLETED) NA Published literature Meta-analysis Intravenous Bronchodilators in Pediatric Critical Asthma: A Systematic Review and Network Meta-Analysis (Pediatric pulmonology, 2025) Meta-analysis Use of intravenous magnesium sulfate in addition to standard first-line treatment with inhaled/nebulised short-acting beta 2 agonist and systemic steroids in the management of acute asthma exacerbations in children: a systematic review and meta-analyses of randomised controlled trials (Archives of disease in childhood, 2025) Meta-analysis Second-line treatment option for children aged 18 years and under with an acute severe asthma exacerbation: a systematic review and meta-analysis of randomised controlled trials (Archives of disease in childhood, 2025) Meta-analysis [Efficacy and safety of magnesium sulfate in the treatment of adult patients with acute severe asthma: a Meta-analysis] (Zhonghua wei zhong bing ji jiu yi xue, 2024) Meta-analysis Role of nebulised magnesium sulfate in treating acute asthma in children: a systematic review and meta-analysis (BMJ paediatrics open, 2024) Systematic review Effectiveness and Safety of Nebulized Magnesium as Last Line Treatment in Adults with Acute Asthma Attack: A Systematic Review and Meta-Analysis (Acta medica Indonesiana, 2024) Clinical trial publication The usefulness of the new SOBIstat-F(®) device in children with severe acute asthma attacks in the emergency department: a randomized clinical trial (The Journal of asthma : official journal of the Association for the Care of Asthma, 2026) Clinical trial publication Intravenous Magnesium: Prompt use for Asthma in Children Treated in the Emergency Department (IMPACT-ED), a pilot randomized trial (Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2025) Clinical trial publication Pharmacokinetics and Pharmacodynamics of Intravenous Magnesium Sulfate in Pediatric Acute Asthma Exacerbations (Journal of clinical pharmacology, 2025) Clinical trial publication Inhaled magnesium versus inhaled salbutamol in rescue treatment for moderate and severe asthma exacerbations in pediatric patients (Jornal de pediatria, 2024) Clinical trial publication Nebulized Salbutamol with or without Magnesium Sulphate in the Management of Acute Asthma in Children in India: A Randomized Controlled Trial (Journal of tropical pediatrics, 2022) CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Vitamin E Natural product Cochrane review Vitamins C and E for asthma and exercise-induced bronchoconstriction Meta-analysis Vitamin A, C and/or E Intake During Pregnancy and Offspring Respiratory… Meta-analysis Does vitamin E prevent asthma or wheeze in children: A systematic revie…	Nutraceutical	Phase II	Moderate	20	8 trials 1 Cochrane 5 Meta-analysis 13 RCT View evidence Registry trials NCT01317563 — Antioxidant Therapy in Lean and Obese Asthmatics (COMPLETED) PHASE2 NCT01661530 — Piloting a Dietary Vitamin E Intervention During Pregnancy (COMPLETED) NA NCT00672529 — Orthomolecular Therapy and Asthma in Children (UNKNOWN) PHASE2 NCT02104505 — Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS (COMPLETED) PHASE1, PHASE2 NCT00466596 — Effect of House Dust Mite Allergen Challenge in Persons Using 1200 mg Gamma Tocopherol Supplements (COMPLETED) PHASE1 NCT00836368 — In Vitro Basophil Responsiveness to Allergen Challenge After Gamma-tocopherol Supplementation in Allergic Asthmatics (COMPLETED) PHASE1 NCT00581048 — Study on the Role of Treatment With Vitamin E on Asthmatic Responses in Allergic Asthmatics (COMPLETED) NA NCT00386178 — Safety Study of a Vitamin E Supplement in Normal Volunteers and Those With Both Allergy and Asthma (COMPLETED) PHASE1 Published literature Cochrane review Vitamins C and E for asthma and exercise-induced bronchoconstriction (The Cochrane database of systematic reviews, 2014) Meta-analysis Vitamin A, C and/or E Intake During Pregnancy and Offspring Respiratory Health: A Systematic Review and Meta-Analysis (Journal of human nutrition and dietetics : the official journal of the British Dietetic Association, 2025) Meta-analysis Does vitamin E prevent asthma or wheeze in children: A systematic review and meta-analysis (Paediatric respiratory reviews, 2018) Meta-analysis Maternal nutrition during pregnancy and risk of asthma, wheeze, and atopic diseases during childhood: a systematic review and meta-analysis (Allergy, 2015) Meta-analysis Association between antioxidant vitamins and asthma outcome measures: systematic review and meta-analysis (Thorax, 2009) Meta-analysis Observational studies on the effect of dietary antioxidants on asthma: a meta-analysis (Respirology (Carlton, Vic.), 2008) Randomized controlled trial Short course gamma tocopherol did not mitigate effects of ozone on airway inflammation in asthmatics (Inhalation toxicology, 2020) Randomized controlled trial Integrative analysis of the intestinal metabolome of childhood asthma (The Journal of allergy and clinical immunology, 2019) Randomized controlled trial Gamma tocopherol-enriched supplement reduces sputum eosinophilia and endotoxin-induced sputum neutrophilia in volunteers with asthma (The Journal of allergy and clinical immunology, 2018) Randomized controlled trial Vitamin e supplementation, lung functions and clinical manifestations in children with moderate asthma: a randomized double blind placebo- controlled trial (Iranian journal of allergy, asthma, and immunology, 2014) Randomized controlled trial Vitamin E, γ-tocopherol, reduces airway neutrophil recruitment after inhaled endotoxin challenge in rats and in healthy volunteers (Free radical biology & medicine, 2013) CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Vitamin D3 Natural product Cochrane review Vitamin D supplementation decrease asthma exacerbations in children: a… Cochrane review Vitamin D for the management of asthma Meta-analysis Prenatal vitamin D supplementation reduces risk of asthma/recurrent whe…	Nutraceutical	Phase III	Emerging	19	8 trials 2 Cochrane 3 Meta-analysis 22 Trial pubs 20 RCT View evidence Registry trials NCT01432678 — Vitamin D Status in Pediatric Asthma (COMPLETED) NCT00856947 — Vitamin D Supplementation During Pregnancy for Prevention of Asthma in Childhood (ACTIVE_NOT_RECRUITING) PHASE1 NCT02880930 — Optimizing Vitamin D Status in Children With Wheeze / Asthma (OPTIVIT) (COMPLETED) NA NCT03880734 — This Study Include Asthma Chronic Obstructive Pulmonary Disease (COPD) Overlap Patients.Patients Were Vitamin D Deficient.Age Range 40-70 Years, Smokers.Patients Were Advised to Take Either Placebo or Vitamin D3.Lung Functions and Exercise Tolerance Were Assessed at Baseline and at 26th Weeks. (COMPLETED) PHASE2 NCT03773809 — Impact of Vitamin D3 Administration on Cardiac Autonomic Tone in Asthma Chronic Obstructive Pulmonary Disease(COPD) Overlap Patients (COMPLETED) NA NCT02197702 — Vitamin D in Preschoolers With Viral-induced Asthma (COMPLETED) PHASE2, PHASE3 NCT01234909 — Asthma, Missed Immunizations, and Vitamin D Deficiency in Atopic Dermatitis (TERMINATED) NCT04179461 — Personalized Treatment Algorithms for Difficult-to-treat Asthma (COMPLETED) PHASE2 Published literature Cochrane review Vitamin D supplementation decrease asthma exacerbations in children: a systematic review and meta-analysis of randomized controlled trials (Annals of medicine, 2024) Cochrane review Vitamin D for the management of asthma (The Cochrane database of systematic reviews, 2023) Meta-analysis Prenatal vitamin D supplementation reduces risk of asthma/recurrent wheeze in early childhood: A combined analysis of two randomized controlled trials (PloS one, 2017) Systematic review Nutritional Interventions to Improve Asthma-Related Outcomes through Immunomodulation: A Systematic Review (Nutrients, 2020) Clinical trial publication Exploratory pilot trial of a multicomponent immunonutritional supplement in children with allergic asthma and rhinitis: The INAPRA study (International immunopharmacology, 2026) Clinical trial publication Does Vitamin D₃ Supplementation Improve Cardiac Autonomic Nerve Function in Vitamin D₃ Deficient Asthma COPD Overlap (ACO) Patients? A Randomized Clinical Trial (Mymensingh medical journal : MMJ, 2025) Clinical trial publication Effect of age and body mass index on vitamin D level in children with asthma in Riyadh (Scientific reports, 2021) Clinical trial publication Effect of Monthly Vitamin D Supplementation on Preventing Exacerbations of Asthma or Chronic Obstructive Pulmonary Disease in Older Adults: Post Hoc Analysis of a Randomized Controlled Trial (Nutrients, 2021) Clinical trial publication Effect of Vitamin D3 Supplementation on Severe Asthma Exacerbations in Children With Asthma and Low Vitamin D Levels: The VDKA Randomized Clinical Trial (JAMA, 2020) Randomized controlled trial Association of serum 25-OH vitamin D₃ with serum IgE and the Pediatric Asthma Severity Score in patients with pediatric asthma (Allergy and asthma proceedings, 2020) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov, Examine.com	PubChem Examine.com
Pycnogenol Natural product Cochrane review Pycnogenol® (extract of French maritime pine bark) for the treatment of… Cochrane review Pycnogenol(®) for the treatment of chronic disorders Systematic review Herbal interventions for chronic asthma in adults and children: a syste…	Botanical	Preclinical	Moderate	17	1 trials 2 Cochrane 1 RCT View evidence Registry trials NCT07536178 — Lungs on Fire: Wildfire Smoke, Incident Diseases, Susceptible Populations, and Community Values in Canada (NOT_YET_RECRUITING) NA Published literature Cochrane review Pycnogenol® (extract of French maritime pine bark) for the treatment of chronic disorders (The Cochrane database of systematic reviews, 2012) Cochrane review Pycnogenol(®) for the treatment of chronic disorders (The Cochrane database of systematic reviews, 2012) Systematic review Herbal interventions for chronic asthma in adults and children: a systematic review and meta-analysis (Primary care respiratory journal : journal of the General Practice Airways Group, 2010) CT.gov search · Cochrane · PubMed	Examine.com	Examine.com
Moringa Natural product Unraveling the metabolic potential of Moringa oleifera derived metaboli… Traditional Herbal Plants and their Phytoconstituents Based Remedies fo… Moringa oleifera: a valuable insight into recent advances in medicinal…	Botanical	Preclinical	Moderate	17	No indexed hits View evidence CT.gov search · Cochrane · PubMed	Examine.com	Examine.com
Spirulina Natural product Study of the spread of medicinal herbs use among patients suffering fro… Therapeutic efficacy of spirulina against ovalbumin and cigarette smoke… Review - Nutraceuticals Can Target Asthmatic Bronchoconstriction: NADPH…	Nutraceutical	Preclinical	Moderate	17	No indexed hits View evidence CT.gov search · Cochrane · PubMed	Examine.com	Examine.com
L-Citrulline Natural product Cochrane review [The role of fractional nitric oxide in exhaled breath (FeNO) in clinic… Clinical trial publication L-Citrulline increases nitric oxide and improves control in obese asthm…	Amino acid	Phase II	Moderate	17	4 trials 1 Cochrane 1 Trial pubs 1 RCT View evidence Registry trials NCT03885245 — Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes (RECRUITING) PHASE2 NCT01715844 — L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics (COMPLETED) PHASE1 NCT05259904 — Study to Improve Deployment Related Asthma by Using L-Citrulline Supplementation (RECRUITING) PHASE2 NCT02943161 — Asthma L-Citrulline Pilot Study (COMPLETED) NA Published literature Cochrane review [The role of fractional nitric oxide in exhaled breath (FeNO) in clinical practice of asthma] (Rinsho byori. The Japanese journal of clinical pathology, 2014) Clinical trial publication L-Citrulline increases nitric oxide and improves control in obese asthmatics (JCI insight, 2019) CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Boswellia Natural product	Botanical	Preclinical	Moderate	17	1 Meta-analysis 2 Trial pubs View evidence CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Saffron Natural product Randomized controlled trial An evaluation of the effects of saffron supplementation on the asthma c… Randomized controlled trial An evaluation of the effect of saffron supplementation on the antibody…	Botanical	Preclinical	Moderate	17	2 RCT View evidence Published literature Randomized controlled trial An evaluation of the effects of saffron supplementation on the asthma clinical symptoms and asthma severity in patients with mild and moderate persistent allergic asthma: a double-blind, randomized placebo-controlled trial (Respiratory research, 2019) Randomized controlled trial An evaluation of the effect of saffron supplementation on the antibody titer to heat-shock protein (HSP) 70, hsCRP and spirometry test in patients with mild and moderate persistent allergic asthma: A triple-blind, randomized placebo-controlled trial (Respiratory medicine, 2018) CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Black Seed Oil Natural product Meta Analysis, Review Effects of Nigella sativa and its constituents on total white blood cel… Meta Analysis Nigella sativa supplementation may provide additional benefits for the… Meta Analysis Nigella sativa supplementation may provide additional benefits for the…	Botanical	Phase II	Moderate	17	2 trials View evidence Registry trials NCT02407262 — Potential Benefits of Black Seed Oil Supplementation on Asthma Inflammation and Outcomes (COMPLETED) PHASE2 NCT07315555 — Efficacy of Oral Nigella Sativa as Adjuvant Therapy in Children With Moderate Persistent Asthma (NOT_YET_RECRUITING) NA CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
L-Carnitine Natural product	Amino acid	Phase III	Moderate	17	1 trials View evidence Registry trials NCT05632549 — The Possible Efficacy and Safety of L-carnitine and Biotin as Adjunctive Therapies in Children With Moderate Persistent Asthma (UNKNOWN) PHASE3 CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
L-Citrulline Natural product Cochrane review [The role of fractional nitric oxide in exhaled breath (FeNO) in clinic… Clinical trial publication L-Citrulline increases nitric oxide and improves control in obese asthm…	Amino acid	Phase II	Emerging	16	4 trials 1 Cochrane 1 Trial pubs 1 RCT View evidence Registry trials NCT03885245 — Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes (RECRUITING) PHASE2 NCT01715844 — L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics (COMPLETED) PHASE1 NCT05259904 — Study to Improve Deployment Related Asthma by Using L-Citrulline Supplementation (RECRUITING) PHASE2 NCT02943161 — Asthma L-Citrulline Pilot Study (COMPLETED) NA Published literature Cochrane review [The role of fractional nitric oxide in exhaled breath (FeNO) in clinical practice of asthma] (Rinsho byori. The Japanese journal of clinical pathology, 2014) Clinical trial publication L-Citrulline increases nitric oxide and improves control in obese asthmatics (JCI insight, 2019) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov, Examine.com	PubChem Examine.com
Magnesium Natural product Meta-analysis Intravenous Bronchodilators in Pediatric Critical Asthma: A Systematic… Meta-analysis Use of intravenous magnesium sulfate in addition to standard first-line… Meta-analysis Second-line treatment option for children aged 18 years and under with…	Nutraceutical	Phase III	Emerging	10	8 trials 26 Meta-analysis 94 Trial pubs 84 RCT View evidence Registry trials NCT03296579 — Non-invasive Ventilation vs. Standard Therapy for Children Hospitalized With an Acute Exacerbation of Asthma (UNKNOWN) NA NCT06626620 — Randomized Controlled Trial of Intravenous Magnesium Sulfate Versus Terbutaline for Children in the Management of Acute Exacerbation of Asthma (COMPLETED) PHASE3 NCT01856959 — Lung Function Changes of Induced Asthma Children Treated With Inhaled MgSO4 (COMPLETED) NA NCT01209026 — Corrected QT (QTc) Study With Flucticasone Furoate and GW642444 (COMPLETED) PHASE1 NCT03880734 — This Study Include Asthma Chronic Obstructive Pulmonary Disease (COPD) Overlap Patients.Patients Were Vitamin D Deficient.Age Range 40-70 Years, Smokers.Patients Were Advised to Take Either Placebo or Vitamin D3.Lung Functions and Exercise Tolerance Were Assessed at Baseline and at 26th Weeks. (COMPLETED) PHASE2 NCT02135718 — ELLIPTA™ vs. MDI Inhaler Preference Study, in Adult Subjects With Asthma (COMPLETED) NCT05166811 — Timely Intravenous Magnesium for Asthma in Children (COMPLETED) PHASE2 NCT01113138 — Study of the Metabolism of Two Magnesium Supplements in Healthy Volunteers (COMPLETED) NA Published literature Meta-analysis Intravenous Bronchodilators in Pediatric Critical Asthma: A Systematic Review and Network Meta-Analysis (Pediatric pulmonology, 2025) Meta-analysis Use of intravenous magnesium sulfate in addition to standard first-line treatment with inhaled/nebulised short-acting beta 2 agonist and systemic steroids in the management of acute asthma exacerbations in children: a systematic review and meta-analyses of randomised controlled trials (Archives of disease in childhood, 2025) Meta-analysis Second-line treatment option for children aged 18 years and under with an acute severe asthma exacerbation: a systematic review and meta-analysis of randomised controlled trials (Archives of disease in childhood, 2025) Meta-analysis [Efficacy and safety of magnesium sulfate in the treatment of adult patients with acute severe asthma: a Meta-analysis] (Zhonghua wei zhong bing ji jiu yi xue, 2024) Meta-analysis Role of nebulised magnesium sulfate in treating acute asthma in children: a systematic review and meta-analysis (BMJ paediatrics open, 2024) Systematic review Effectiveness and Safety of Nebulized Magnesium as Last Line Treatment in Adults with Acute Asthma Attack: A Systematic Review and Meta-Analysis (Acta medica Indonesiana, 2024) Clinical trial publication The usefulness of the new SOBIstat-F(®) device in children with severe acute asthma attacks in the emergency department: a randomized clinical trial (The Journal of asthma : official journal of the Association for the Care of Asthma, 2026) Clinical trial publication Intravenous Magnesium: Prompt use for Asthma in Children Treated in the Emergency Department (IMPACT-ED), a pilot randomized trial (Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2025) Clinical trial publication Pharmacokinetics and Pharmacodynamics of Intravenous Magnesium Sulfate in Pediatric Acute Asthma Exacerbations (Journal of clinical pharmacology, 2025) Clinical trial publication Inhaled magnesium versus inhaled salbutamol in rescue treatment for moderate and severe asthma exacerbations in pediatric patients (Jornal de pediatria, 2024) Clinical trial publication Nebulized Salbutamol with or without Magnesium Sulphate in the Management of Acute Asthma in Children in India: A Randomized Controlled Trial (Journal of tropical pediatrics, 2022) CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Vitamin E Natural product Cochrane review Vitamins C and E for asthma and exercise-induced bronchoconstriction Meta-analysis Vitamin A, C and/or E Intake During Pregnancy and Offspring Respiratory… Meta-analysis Does vitamin E prevent asthma or wheeze in children: A systematic revie…	Nutraceutical	Phase II	Emerging	10	8 trials 1 Cochrane 5 Meta-analysis 13 RCT View evidence Registry trials NCT01317563 — Antioxidant Therapy in Lean and Obese Asthmatics (COMPLETED) PHASE2 NCT01661530 — Piloting a Dietary Vitamin E Intervention During Pregnancy (COMPLETED) NA NCT00672529 — Orthomolecular Therapy and Asthma in Children (UNKNOWN) PHASE2 NCT02104505 — Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS (COMPLETED) PHASE1, PHASE2 NCT00466596 — Effect of House Dust Mite Allergen Challenge in Persons Using 1200 mg Gamma Tocopherol Supplements (COMPLETED) PHASE1 NCT00836368 — In Vitro Basophil Responsiveness to Allergen Challenge After Gamma-tocopherol Supplementation in Allergic Asthmatics (COMPLETED) PHASE1 NCT00581048 — Study on the Role of Treatment With Vitamin E on Asthmatic Responses in Allergic Asthmatics (COMPLETED) NA NCT00386178 — Safety Study of a Vitamin E Supplement in Normal Volunteers and Those With Both Allergy and Asthma (COMPLETED) PHASE1 Published literature Cochrane review Vitamins C and E for asthma and exercise-induced bronchoconstriction (The Cochrane database of systematic reviews, 2014) Meta-analysis Vitamin A, C and/or E Intake During Pregnancy and Offspring Respiratory Health: A Systematic Review and Meta-Analysis (Journal of human nutrition and dietetics : the official journal of the British Dietetic Association, 2025) Meta-analysis Does vitamin E prevent asthma or wheeze in children: A systematic review and meta-analysis (Paediatric respiratory reviews, 2018) Meta-analysis Maternal nutrition during pregnancy and risk of asthma, wheeze, and atopic diseases during childhood: a systematic review and meta-analysis (Allergy, 2015) Meta-analysis Association between antioxidant vitamins and asthma outcome measures: systematic review and meta-analysis (Thorax, 2009) Meta-analysis Observational studies on the effect of dietary antioxidants on asthma: a meta-analysis (Respirology (Carlton, Vic.), 2008) Randomized controlled trial Short course gamma tocopherol did not mitigate effects of ozone on airway inflammation in asthmatics (Inhalation toxicology, 2020) Randomized controlled trial Integrative analysis of the intestinal metabolome of childhood asthma (The Journal of allergy and clinical immunology, 2019) Randomized controlled trial Gamma tocopherol-enriched supplement reduces sputum eosinophilia and endotoxin-induced sputum neutrophilia in volunteers with asthma (The Journal of allergy and clinical immunology, 2018) Randomized controlled trial Vitamin e supplementation, lung functions and clinical manifestations in children with moderate asthma: a randomized double blind placebo- controlled trial (Iranian journal of allergy, asthma, and immunology, 2014) Randomized controlled trial Vitamin E, γ-tocopherol, reduces airway neutrophil recruitment after inhaled endotoxin challenge in rats and in healthy volunteers (Free radical biology & medicine, 2013) CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Omega-3 Fatty Acids Natural product Clinical trial publication Fish Oil Supplementation in Overweight/Obese Patients with Uncontrolled… Clinical trial publication Efficacy of a Mediterranean diet supplemented with fatty fish in amelio… Clinical trial publication Lung VITAL: Rationale, design, and baseline characteristics of an ancil…	Nutraceutical	Phase III	Emerging	10	8 trials 3 Cochrane 16 Trial pubs View evidence Registry trials NCT00801502 — Salmon in Pregnancy Study (COMPLETED) NA NCT01200446 — Effect of a Component of Fish Oil on Exercise-Induced Bronchoconstriction and Airway Inflammation in Asthma (COMPLETED) NA NCT00798226 — Fish Oil Supplementation During Pregnancy for Prevention of Asthma, Eczema and Allergies in Childhood (ACTIVE_NOT_RECRUITING) PHASE1 NCT06560255 — Fish Oil in pREgnancY for Personalized Prevention of Early Childhood Asthma (RECRUITING) PHASE3 NCT02064738 — High Omega-3/Low Omega-6 Treatment Diet for Aspirin-exacerbated Respiratory Disease (AERD) (COMPLETED) NA NCT01996891 — Asthma (and Dietary) Inflammation Reduction (TERMINATED) NA NCT01473823 — Treatment of IgE Associated Eczema With Omega-3 Long Chain Polyunsaturated Fatty Acids in Infancy and the Development of Bronchial Asthma in Childhood (UNKNOWN) NA NCT01027143 — Obesity and Asthma: Nutrigenetic Response to Omega-3 Fatty Acids (COMPLETED) PHASE2, PHASE3 Published literature Clinical trial publication Fish Oil Supplementation in Overweight/Obese Patients with Uncontrolled Asthma. A Randomized Trial (Annals of the American Thoracic Society, 2019) Clinical trial publication Efficacy of a Mediterranean diet supplemented with fatty fish in ameliorating inflammation in paediatric asthma: a randomised controlled trial (Journal of human nutrition and dietetics : the official journal of the British Dietetic Association, 2019) Clinical trial publication Lung VITAL: Rationale, design, and baseline characteristics of an ancillary study evaluating the effects of vitamin D and/or marine omega-3 fatty acid supplements on acute exacerbations of chronic respiratory disease, asthma control, pneumonia and lung function in adults (Contemporary clinical trials, 2016) Clinical trial publication The effect of omega-3 fatty acids on bronchial hyperresponsiveness, sputum eosinophilia, and mast cell mediators in asthma (Chest, 2015) Clinical trial publication Comparison of essential fatty acid intakes and serum levels of inflammatory factors between asthmatic and healthy adults: a case- control study (Iranian journal of allergy, asthma, and immunology, 2014) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Coleus Forskohlii Natural product Heterologous Production of Forskolin in Tobacco (Nicotiana tabacum) via… Biotechnological interventions for the production of forskolin, an acti… Coleus forskohlii: advancements and prospects of in vitro biotechnology	Nutraceutical	Preclinical	Moderate	10	No indexed hits View evidence CT.gov search · Cochrane · PubMed	Examine.com	Examine.com
Conjugated Linoleic Acid Natural product Effects of a dietary intervention with conjugated linoleic acid on immu… Conjugated linoleic acid improves airway hyper-reactivity in overweight…	Nutraceutical	Phase II	Moderate	10	3 trials 3 Trial pubs View evidence Registry trials NCT01026506 — c9,t11-CLA in Children and Adolescents With Allergic Asthma (COMPLETED) NA NCT02433977 — The Effects of NOx and Conjugated Linoleic Acid on Asthmatics (COMPLETED) PHASE2 NCT00876356 — The Health Benefits of Conjugated Linoleic Acid (CLA) for Asthma & Allergy (COMPLETED) NA CT.gov search · Cochrane · PubMed	Examine.com	Examine.com
Vitamin C Natural product Human Study These findings suggest that higher vitamin C intake may play a potentia… Human Study A significant association was observed between duration of asthma and p… Meta Analysis, Review Asthmatic children had lower 25(OH)D levels as compared to nonasthmatic…	Nutraceutical	Phase III	Emerging	10	8 trials 8 Cochrane 14 Trial pubs View evidence Registry trials NCT03203603 — VCSIP Follow-up Study (COMPLETED) NCT03206710 — Vitamin C Supplementation to Pregnant Smokers: Follow-up of 2 Randomized Trials Plus Changes in DNA Methylation (COMPLETED) NCT01057615 — Effect of Fish Oil and Vitamin C on Exercise-Induced Bronchoconstriction and Airway Inflammation in Asthma (COMPLETED) PHASE1 NCT05728385 — Impact of Modified Specific Carbohydrate Diet on Bronchial Asthma Control in Children (UNKNOWN) NA NCT01317563 — Antioxidant Therapy in Lean and Obese Asthmatics (COMPLETED) PHASE2 NCT00672529 — Orthomolecular Therapy and Asthma in Children (UNKNOWN) PHASE2 NCT01759472 — Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Provocation Test (UNKNOWN) NCT02734446 — To Evaluate the Efficacy of Supplementation With L. Reuteri + Vit. D3 in Asthmatic Children (COMPLETED) PHASE3 CT.gov search · Cochrane · PubMed		PubChem
Zinc Natural product Meta Analysis Lower circulating zinc and selenium levels might be associated with an… Human Study Adding nebulized magnesium sulfate to standard therapy in patients with… Human Study Atopic asthmatics might benefit from zinc supplements.	Nutraceutical	Preclinical	Emerging	10	—		PubChem
Omega-3 Fatty Acids Natural product Clinical trial publication Fish Oil Supplementation in Overweight/Obese Patients with Uncontrolled… Clinical trial publication Efficacy of a Mediterranean diet supplemented with fatty fish in amelio… Clinical trial publication Lung VITAL: Rationale, design, and baseline characteristics of an ancil…	Nutraceutical	Phase III	Emerging	10	8 trials 3 Cochrane 16 Trial pubs View evidence Registry trials NCT00801502 — Salmon in Pregnancy Study (COMPLETED) NA NCT01200446 — Effect of a Component of Fish Oil on Exercise-Induced Bronchoconstriction and Airway Inflammation in Asthma (COMPLETED) NA NCT00798226 — Fish Oil Supplementation During Pregnancy for Prevention of Asthma, Eczema and Allergies in Childhood (ACTIVE_NOT_RECRUITING) PHASE1 NCT06560255 — Fish Oil in pREgnancY for Personalized Prevention of Early Childhood Asthma (RECRUITING) PHASE3 NCT02064738 — High Omega-3/Low Omega-6 Treatment Diet for Aspirin-exacerbated Respiratory Disease (AERD) (COMPLETED) NA NCT01996891 — Asthma (and Dietary) Inflammation Reduction (TERMINATED) NA NCT01473823 — Treatment of IgE Associated Eczema With Omega-3 Long Chain Polyunsaturated Fatty Acids in Infancy and the Development of Bronchial Asthma in Childhood (UNKNOWN) NA NCT01027143 — Obesity and Asthma: Nutrigenetic Response to Omega-3 Fatty Acids (COMPLETED) PHASE2, PHASE3 Published literature Clinical trial publication Fish Oil Supplementation in Overweight/Obese Patients with Uncontrolled Asthma. A Randomized Trial (Annals of the American Thoracic Society, 2019) Clinical trial publication Efficacy of a Mediterranean diet supplemented with fatty fish in ameliorating inflammation in paediatric asthma: a randomised controlled trial (Journal of human nutrition and dietetics : the official journal of the British Dietetic Association, 2019) Clinical trial publication Lung VITAL: Rationale, design, and baseline characteristics of an ancillary study evaluating the effects of vitamin D and/or marine omega-3 fatty acid supplements on acute exacerbations of chronic respiratory disease, asthma control, pneumonia and lung function in adults (Contemporary clinical trials, 2016) Clinical trial publication The effect of omega-3 fatty acids on bronchial hyperresponsiveness, sputum eosinophilia, and mast cell mediators in asthma (Chest, 2015) Clinical trial publication Comparison of essential fatty acid intakes and serum levels of inflammatory factors between asthmatic and healthy adults: a case- control study (Iranian journal of allergy, asthma, and immunology, 2014) CT.gov search · Cochrane · PubMed		PubChem
Lycopene Natural product Human Study Lycopene may positively modify clinical asthma outcomes.	Food compound	Preclinical	Emerging	10	—		PubChem
Caffeine Natural product	Food compound	Preclinical	Moderate	10	—	Examine.com	PubChem Examine.com
Saffron Natural product Randomized controlled trial An evaluation of the effects of saffron supplementation on the asthma c… Randomized controlled trial An evaluation of the effect of saffron supplementation on the antibody…	Botanical	Preclinical	Emerging	7	2 RCT View evidence Published literature Randomized controlled trial An evaluation of the effects of saffron supplementation on the asthma clinical symptoms and asthma severity in patients with mild and moderate persistent allergic asthma: a double-blind, randomized placebo-controlled trial (Respiratory research, 2019) Randomized controlled trial An evaluation of the effect of saffron supplementation on the antibody titer to heat-shock protein (HSP) 70, hsCRP and spirometry test in patients with mild and moderate persistent allergic asthma: A triple-blind, randomized placebo-controlled trial (Respiratory medicine, 2018) CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Black Seed Oil Natural product Meta Analysis, Review Effects of Nigella sativa and its constituents on total white blood cel… Meta Analysis Nigella sativa supplementation may provide additional benefits for the… Meta Analysis Nigella sativa supplementation may provide additional benefits for the…	Botanical	Phase II	Emerging	7	2 trials View evidence Registry trials NCT02407262 — Potential Benefits of Black Seed Oil Supplementation on Asthma Inflammation and Outcomes (COMPLETED) PHASE2 NCT07315555 — Efficacy of Oral Nigella Sativa as Adjuvant Therapy in Children With Moderate Persistent Asthma (NOT_YET_RECRUITING) NA CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Boswellia Natural product A Standardized Boswellia serrata Extract Improves Knee Joint Function a… Anti-inflammatory and anti-cancer activities of frankincense: Targets,… Functional study on Boswellia phytosome as complementary intervention i…	Botanical	Preclinical	Emerging	7	1 Meta-analysis 2 Trial pubs View evidence CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
L-Carnitine Natural product Deficiency of Mitochondrial Fatty Acid Enzyme, CPT1A, Underlies Airway… Multi-Omics Analysis Reveals New Insights into Yak Lung Under High-Alti… Microbial and metabolomic profiling of the upper respiratory tract in c…	Amino acid	Phase III	Emerging	7	1 trials View evidence Registry trials NCT05632549 — The Possible Efficacy and Safety of L-carnitine and Biotin as Adjunctive Therapies in Children With Moderate Persistent Asthma (UNKNOWN) PHASE3 CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Selenium Natural product Meta Analysis Lower circulating zinc and selenium levels might be associated with an… Human Study Low serum levels of zinc, selenium, and vitamin D3 are biomarkers of ai…	Nutraceutical	Preclinical	Emerging	7	—	ClinicalTrials.gov	PubChem
Cordyceps Natural product Human Study Dongchongxiacao (Cordyceps) can reduce serum markers of airway inflamma… Human Study Green tea (Camelia sinensis) mediated suppression of IgE production by…	Mushroom	Preclinical	Emerging	7	—		—
Selenium Natural product Meta Analysis Lower circulating zinc and selenium levels might be associated with an… Human Study Low serum levels of zinc, selenium, and vitamin D3 are biomarkers of ai…	Nutraceutical	Preclinical	Emerging	7	—		PubChem
Curcumin Natural product Human Study Curcumin has value as an add=on therapy in patients with bronchial asth…	Food compound	Preclinical	Emerging	7	—		PubChem
Lactobacillus Natural product Human Study Efficacy and safety of Lactobacillus reuteri CCFM1040 in allergic rhini… Human Study Efficacy of Lactobacillus administration in school-age children with as… Human Study EHCF+LGG reduces the incidence of other allergic manifestations and has…	Probiotic	Preclinical	Emerging	7	—		—
Egcg Natural product Human Study Green tea (Camelia sinensis) mediated suppression of IgE production by… Human Study Green-lipped mussel exhibits beneficial effects in patients with atopic…	Food compound	Preclinical	Emerging	7	—		PubChem
Grape Seed Extract Natural product Human Study Nrf2 regulates downstream genes by targeting miR-29b in severe asthma a…	Botanical	Preclinical	Emerging	7	—		—
Sulforaphane Natural product A Randomized Controlled Trial of the Effect of Broccoli Sprouts on Anti…	Food compound	Preclinical	Emerging	7	—		PubChem
Fenugreek Natural product Fenugreek Herbs use in Saudi children with acute respiratory illnesses Investigating the effectiveness of the Trigonella foenum-graecum L. (fe…	Botanical	Preclinical	Emerging	7	—		—
Niacin Natural product Meta Analysis, Review Asthmatic children had lower 25(OH)D levels as compared to nonasthmatic… Meta Analysis In people with predominantly mild to moderate asthma suggests that vita… Meta Analysis Vitamin D supplementation reduced the rate of asthma exacerbation, espe…	Nutraceutical	Preclinical	Emerging	7	—		PubChem
Ginkgo Biloba Natural product Human Study Ginkgo biloba may be an ideal complement to the glucocorticosteroid the…	Botanical	Preclinical	Emerging	2	—		—
Cgs-15943 Natural product Impact of the cAMP efflux and extracellular cAMP-adenosine pathway on a… Adenosine-induced bronchoconstriction and contraction of airway smooth…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Neca Natural product Adenosine restrains ILC2-driven allergic airway inflammation via A2A re… Limonene-induced activation of A(2A) adenosine receptors reduces airway… Adenosine activates Gα(s) proteins and inhibits C3a-induced activation…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Tamsulosin Natural product Importance of Alpha-adrenergic Receptor Subtypes in Regulating of Airwa… Montelukast for symptom control of interstitial cystitis A case of gastrointestinal stromal tumor diagnosed on prostate biopsy	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Terazosin Natural product DA1 receptors modulation in rat isolated trachea Antihypertensive therapy in the geriatric patient: II. A review of the…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Yohimbine Natural product Dexmedetomidine Protects against Airway Inflammation and Airway Remodel… Dexmedetomidine reduces IL-4 and IgE expression through downregulation… DA1 receptors modulation in rat isolated trachea	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Indoramin Natural product Antihypertensive therapy in the geriatric patient: II. A review of the… [Respiratory effects of antihypertensive agents acting on alpha adrener… Is indoramin useful in the treatment of bronchial asthma?	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Phentolamine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Prazosin Natural product Prazosin, an alpha 1-adrenoceptor antagonist, partially inhibits exerci… Inhaled prazosin in asthma	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Zm-241385 Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Clonidine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Apraclonidine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Doxazosin Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Mianserin Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Akuammigine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Rauwolscine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Corynantheine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Oxymetazoline Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
1,3-DIPROPYL-8-CYCLOPENTYLXANTHINE [Dpcpx] Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
8-PHENYL Theophylline Natural product Human Study Zataria multiflora induced bronchodilatoion comparable to theophylline…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Namodenoson Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Atipamezole Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Vancomycin Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Desglymidodrine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Phenylpropanolamine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Dexniguldipine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Niguldipine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Alprenolol Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Betaxolol Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Carteolol Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Propranolol Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Caffeine Natural product Metabolite signatures associated with microRNA miR-143-3p serve as driv… Chronic coffee consumption and respiratory disease: A systematic review Diet effects in the asthma treatment: A systematic review	Food compound	Preclinical	Emerging	0	—	Examine.com	PubChem Examine.com
Nigella Sativa (Aka Black Seed) Natural product Meta Analysis, Review Effects of Nigella sativa and its constituents on total white blood cel… Meta Analysis Nigella sativa supplementation may provide additional benefits for the… Meta Analysis Nigella sativa supplementation may provide additional benefits for the…	Nutraceutical	Preclinical	Emerging	0	—		—
Flavonoids Natural product	Nutraceutical	Preclinical	Emerging	0	—		—
Magnesium Sulfate Natural product Meta Analysis This review provides evidence that a single infusion of 1.2 g or 2 g IV… Human Study Adding nebulized magnesium sulfate to standard therapy in patients with… Human Study Early use of high-dose prolonged magnesium sulfate infusion for asthma…	Nutraceutical	Preclinical	Emerging	0	—		—
Zataria Multiflora Natural product Human Study Zataria multiflora induced bronchodilatoion comparable to theophylline…	Nutraceutical	Preclinical	Emerging	0	—		—
Fruit: All Natural product Meta Analysis, Review Greater fruit and vegetables consumption, and adherence to a Mediterran… Meta Analysis High intake of fruit and vegetables may reduce the risk of asthma and w… Human Study Increasing fruit and vegetable intake could be an effective non-pharmac…	Nutraceutical	Preclinical	Emerging	0	—		—
Vegetables: All Natural product Meta Analysis, Review Greater fruit and vegetables consumption, and adherence to a Mediterran… Meta Analysis High intake of fruit and vegetables may reduce the risk of asthma and w… Human Study Increasing fruit and vegetable intake could be an effective non-pharmac…	Nutraceutical	Preclinical	Emerging	0	—		—
Pterostilbene Natural product Meta Analysis The effect of pterostilbene and its active ingredients on experimental…	Nutraceutical	Preclinical	Emerging	0	—		—
Butterbur Natural product Human Study Butterbur confers complementary anti-inflammatory activity in atopic as… Human Study Butterbur is a safe and effective therapy for the treatment of asthma.	Nutraceutical	Preclinical	Emerging	0	—		—
Fucoidan Natural product Human Study Effects of oligo-fucoidan on the immune response, inflammatory status a… Human Study Oligo-fucoidan improved unbalance the Th1/Th2 and Treg/Th17 ratios in a…	Nutraceutical	Preclinical	Emerging	0	—		—
Genistein Natural product Human Study Genistein and puerarin could inhibit the pathway of NF-kappaB and TNF-a… Human Study Increased consumption of genistein is associated with better lung funct…	Food compound	Preclinical	Emerging	0	—		PubChem

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). This page is for research orientation only — not medical advice.